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ABSTRACT
This study associated chemotherapy-related cognitive impairment with
Psychosocial Adjustment and Quality of Life (QOL) in seventy-four colorectal cancer
patients. Assessments included the Cambridge Neuropsychological Test Automated
Battery (CANTAB), Psychosocial Adjustment to Illness Scale - Self Report Version
(PAIS-SR), and Functional Assessment to Cancer Therapy - General Version (FACTG).
The sample consisted of 4 groups: A & C (stage III/ high-risk II), with A assessed
pre-chemotherapy and C post-chemotherapy; and groups B & D (stage I/II) who did not
require chemotherapy, with B assessed post-operatively and D 6-months post-operatively.
A statistically insignificant negative association was found between CANTAB and PAISSR results. The association between PAIS-SR and FACT-G was also negative, was
highly significant, and indicates that as psychosocial adjustment improves, so does QOL.
This study suggests that cognitive changes do not influence patients' relationships
and functional roles, which are strongly associated with QOL.
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Chapter 1
Introduction
An Overview of Colorectal Cancer and Psychosocial Adjustment
The Canadian Cancer Society (CCS) and the National Cancer Institute of Canada
(NCIC) estimate that 166,400 new cases and 73,800 deaths from cancer will occur in
Canada this year. Of these, 21,500 new cases of colorectal cancer will be diagnosed, and
8,900 will die from the disease (Canadian Cancer Society/National Cancer Institute of
Canada, 2008). Colorectal cancer incidence has remained relatively stable for the past
eight years, whereas mortality rates have continued to decline since 1979 (by 1.7% in
females and by 1.3% per year in males). These findings are attributed to increased
attention toward population screening programs, and recognition of colorectal cancer's
modifiable risk factors (Canadian Cancer Society/National Cancer Institute of Canada,
2005), as well as improvements in chemotherapy (Canadian Cancer Society/National
Cancer Institute of Canada, 2008), all of which have led to a longer duration of living
with the illness.
Although chemotherapy has continued to be a standard treatment for colorectal
cancer over the last 40 years (Midgley & Kerr, 2000), it is only within the past two
decades that the impact of treatment upon the patient has been addressed within a holistic
framework. Chemotherapy is often used alone or in combination with radiation for the
post-operative adjuvant treatment of colorectal cancer (Midgley & Kerr, 2000). Physical
side-effects of chemotherapy are well known and managed by the health care team, but
other side-effects, such as changes in cognitive function, have only recently been
acknowledged and are consequently understudied. The needs of the colorectal cancer
patient are multi-factorial and therefore complex.

2

Nursing has a professional responsibility to care for the multi-dimensional needs of
clients. In outlining the competencies related to their standards of practice, the College of
Nurses of Ontario (CNO) directs Registered Nurses to collaborate with clients in a
holistic assessment addressing their physical, emotional, psychological, cognitive, social,
spiritual, developmental, cultural, and educational needs (College of Nurses of Ontario,
1999, p. 15). Other organizations that identify the holistic responsibilities of nurses are
the Canadian Nurses Association (2002) and the American Holistic Nurses' Association
(1994). Thus stated, holistic care is a necessary component of quality nursing care which
benefits the lives of colorectal cancer patient care.
Nursing is not the only health profession interested in caring for the multidimensional needs of cancer patients. In the 1980s, the Canadian Association of
Psychosocial Oncology emerged with the multi-disciplinary intention to research and care
for the psychosocial needs of cancer patients. They characterize psychosocial oncology
as that which strives to understand and treat the "social, psychological, emotional,
spiritual, quality-of-life and functional aspects of cancer" (Canadian Association of
Psychosocial Oncology, 2005). From this definition, it is clear that the aims of
psychosocial and holistic care are similarly multi-dimensional in their scope.
Within the oncology literature, studies have demonstrated the impact that a cancer
diagnosis and treatment have upon a person's psychosocial adjustment (de Paula Lima,
2005; Gilbar & De-Nour, 1989; Kelman, 1997; Wolberg, Romsaas, Tanner, & Malec,
1989). In a phenomenological exploration of a colorectal cancer diagnosis, Taylor (2001)
described the participants' most distressing theme of feeling that they were on their own.
This experience was generated by the subjects' personal reflection of themselves, values,
beliefs and accomplishments, as well as their desire to protect loved ones from details of
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the diagnosis and treatment. Additionally, psychological distress related to the frequency
of existential thoughts has been found to occur in over 93% of those diagnosed with
colorectal cancer (Klemm, Miller, & Fernsler, 2000). The differences in psychosocial
adaptation between cancer patients and healthy controls is made clear by Wolberg et al.
(1989) who claim that the issues with adjustment persist for up to 16 months after a
diagnosis. Furthermore, it is the quality of attention given to cancer patients'
psychosocial needs which is correlated with higher patient satisfaction as opposed to the
duration of time spent with patients giving them numerous resources (Walker, Ristvedt, &
Haughey, 2003).
The studies outlined above confirm the impact that a cancer diagnosis has upon
one's psychosocial adjustment. However, the influence that specific symptoms related to
cancer treatment have upon a person's psychosocial adjustment remains unclear. Of
particular interest, is the symptom of cognitive dysfunction related to chemotherapy.
While it is well documented that cognitive decline has been associated with
chemotherapy treatment, particularly for breast cancer, there are few studies relating
chemotherapy-induced cognitive dysfunction and psychosocial issues. This research will
attempt to fill this void in the oncology literature.
Theoretical Framework
The framework used to guide this research is the Theory of Unpleasant Symptoms
developed by Lenz, Suppe, Gift, Pugh, and Milligan (1995). The theory began its
development when three of the investigators began simultaneously working on two
different concepts representing unpleasant symptoms. Initially, two of the investigators
collaborated about their studies of women's fatigue at different phases of the childbearing
process, and then another set of two investigators realized that they were conceptualizing

different concepts in similar terms (Lenz et al.). Collectively, these researchers began to
examine other similar concepts in hopes that they could be formed into a general
framework. Thus began the formulation of The Theory of Unpleasant Symptoms.
The assumption behind the theory is that it can guide research and practice for any
number of symptoms since symptoms share many commonalities (Lenz, Pugh, Milligan,
Gift, & Suppe, 1997). The theory proposes that three categories of influencing factors
(physiologic, psychologic and situational) relate to each other and may individually or
collectively affect the predisposition or manifestation of an unpleasant symptom (Lenz et
al.). In outlining examples of each factor, Lenz et al. describe physiological factors as
normal functioning body systems, existence of pathology or level of energy;
psychological factors as mental state or mood, affective reaction to illness or degree of
uncertainty about symptoms; and situational factors as aspects of the social and physical
environment that may affect the person's experience and reporting of symptoms.
The theory's central concept, the unpleasant symptom(s), is experienced by the
patient and is defined by Hegyvary (as cited in Lenz et al., 1997) as the "perceived
indicators of change in normal functioning as experienced by the patients". One
symptom may occur at a time, although it is more common for more than one symptom to
transpire simultaneously, usually in a catalyzing manner (Lenz et al.). Each symptom is
multi-dimensional, varying in intensity (severity or strength), time (frequency or
duration), distress (irritating or bothersome), and quality (a subjective description) (Lenz
et al.).
The outcome of the symptom impacts the person's functional and/or cognitive
performance. Functional performances may include physical activities, social activities,

interaction and role performances, whereas cognitive performances include concentrating,
thinking and problem-solving (Lenz et al., 1997).
The original, or in-process Theory of Unpleasant Symptoms (1995), posited
unidirectional relationships of the influential factors on symptoms, and symptoms on
performance. In their updated model, Lenz et al., (1997) theorize that relationships
among the concepts may be more reciprocal. They propose that symptoms may affect the
influencing factors, and that performance outcomes may shape the symptom experience
as well as the influential factors. Figure 1 illustrates the relationships between the
concepts within The Theory of Unpleasant Symptoms.
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Figure 1. A diagram depicting the conceptual relationships within the
Theory of Unpleasant Symptoms.
Note. From "The Middle-Range Theory of Unpleasant Symptoms: An
Update," by E. R. Lenz, L. C. Pugh, R. A. Renee, A. Gift and F. Suppe,
1997., Advances in Nursing Science, 19(3), p. 14-27. Copyright 1997 by
Wolters Kluwer Health. Reprinted with permission.
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The Theory of Unpleasant Symptoms was based on inductive and deductive
research, and analyses have shown support for the model in relation to maternal health,
and dyspnea (Lenz et al., 1997). The theory has recently begun to appear within the
oncology literature and has shown support for the relationship between .disease and
treatment-related symptoms upon performance (Robinson, Bradway, Nuamah, Pickett, &
McCorkle, 2008; Thompson, 2006), and that this relationship was strengthened when
symptoms were clustered (Thompson). In using the theory to explore lymphedema
symptoms of breast cancer patients, Ridner (2004) strengthened the theory's claim that
symptoms are multi-dimensional, resulting from combined influencing factors, and that
interventions targeted toward one factor is inadequate in relieving the symptom.
However, Redeker, Lev and Ruggiero (2000) suggest that the effect of symptoms (fatigue
and insomnia) on quality of life decreased in the presence of psychological factors
(depression and anxiety). Due to this difference, and due to the small numbers of
oncology research projects that have explored the relationships within the Theory of
Unpleasant Symptoms, further exploration into cancer and treatment related symptoms is
needed in relation to the theory to more clearly illustrate the relationships among these
concepts.
The concepts explored in this research (cognitive impairment, psychosocial
adjustment and quality of life) can easily be related within the Theory of Unpleasant
Symptoms. The symptom of cognitive impairment that is precipitated by chemotherapy
can affect the ability to perform cognitive tasks. It is these cognitive tasks, or
performance, that objectively indicate that the symptom is present. A poorer performance
in cognitive abilities can affect mood, reaction to illness or uncertainty, known as
psychological factors within the theory. A poorer performance can also affect the social
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environment in which one is involved (situational factor) or their level of energy
(physiological factor). These psychological, situational and physiological factors
encompass many other issues that are comparable to the concepts of psychosocial
adjustment and quality of life, for which there are validated tools to use. Finally, the
effects of the disruptions in these influencing factors can manifest the distress, intensity,
timing and quality of the original symptom, cognitive impairment.
For the purposes of this research, it is the impact of performance outcomes
(chemotherapy-induced cognitive impairment) upon the influencing factors (psychosocial
adjustment and quality of life) that will be explored. In order to explore these
relationships, a review of these concepts within the scholarly literature will be conducted.
An investigation into the oncology literature will take place, with a particular emphasis
upon the experiences involving colorectal cancer patients.
Chapter II
A Review of the Literature
Relationships Between Chemotherapy and Cognitive Dysfunction
The magnitude of cognitive dysfunction associated with chemotherapy
Within the oncology literature, there is growing evidence showing the effects of
chemotherapy upon cognitive function. Most of the research in this area has investigated
women with breast cancer who received adjuvant treatment, and show that as many as 1675% of them show moderate to severe cognitive impairment in a variety of manifestations
(Ahles et al., 2003; Brezden, Phillips, Abdolell, Bunston, & Tannock, 2000; Schagen et
al., 1999; Tannock, Ahles, Ganz, & van Dam, 2004). In fact, as many as 32% of people
receiving high-dose chemotherapy and 28% of those receiving standard or adjuvant
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therapy objectively display post-treatment cognitive impairment (Schagen et al., 1999;
van Dam et al., 1998).
In their comparison of women with breast cancer receiving high-dose
chemotherapy, standard chemotherapy or local radiation therapy, van Dam et al. (1998)
found that women who received standard chemotherapy were 3.5 times more at risk (CI
95%) of developing cognitive impairment as compared to those who received local
treatment. Other studies conducted in non-brain tumor populations have shown similar
results indicating that people who are treated with systemic chemotherapy experience
greater cognitive disturbances than those treated with more localized modalities (Schagen
et al., 1999; Ahles et al., 2005). These studies demonstrate the impact that chemotherapy
has upon the cancer patient's cognitive function. The surplus of research in breast cancer
populations has produced results that are difficult to generalize. Therefore, studies within
other cancer groups is necessary.
The manifestations of chemotherapy-induced cognitive dysfunction
In order to have a detailed discussion about the relationship between cognitive
dysfunction and chemotherapy, it is imperative to understand what is meant by cognitive
dysfunction. Within the research literature, cognitive disturbances vary according to
treatment, but are commonly manifested by subtle declines in memory, concentration,
mental fogginess, and ability to stay focused or organized (Ahles & Saykin, 2001;
Iconomou, Mega, Koutras, Iconomou, & Kalafonos, 2004; Taillibert, Voillery, &
Bernard-Marty, 2007). Studies have captured both subjective and objective details about
these cognitive disturbances, which have (Vardy, 2007) and have not found relationships
to each other (Iconomou et al.; van Dam et al., 1998). Self-reports from patients who
received chemotherapy demonstrate moderate or highly disruptive problems with
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memory or concentration, which is statistically significant over patients in a control group
(Schagen et al., 1999; van Dam et al.).
The duration of chemotherapy-induced cognitive side-effects
The exact duration of cognitive dysfunction lasting beyond the treatment period is
unknown; however, longitudinal studies are ongoing. Initial studies in this area show that
cognitive dysfunction noticed at the completion of treatment can go on for as long as two
years (Bender et al., 2006) and even ten years after chemotherapy is completed (Ahles et
al., 2002). It is interesting to note that the majority of patients in this study received only
one standard-dose chemotherapy regimen, which presents many questions about more
highly cytotoxic regimens or investigational drugs.
The mechanisms of chemotherapy-induced cognitive dysfunction
The exact mechanisms of chemotherapy-induced cognitive dysfunctions are
currently unknown, and continue to be studied. One possible explanation is that
chemotherapy causes neurotoxic damage (Saykin, Ahles, & McDonald, 2003), and
damage can be dependent upon treatment type (Bender et al., 2006; Scheibel, Valentine,
O'Brien, & Meyers, 2004) and dose (Taillibert et al., 2007). Another possible
explanation is having a genetic predisposition toward cognitive impairment. Ahles et al.
(2003) showed that those who received chemotherapy and were carriers of the
apolipoprotein E e4 allele tended to score lower on various neuropsychological tests than
survivors with other alleles of lipoprotein. Other explanations could be related to the
function of cytokines, which are small proteins within the body used to regulate immunity
and inflammation, even functioning as growth factors (Fox, 1996). Studies have shown
that elevated cytokine levels increase lethargy and impair learning (Banks, Farr, &
Morley, 2003; Slaviero, Clarke, & Rivory, 2003). However, when exploring the IL-1/?,
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IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, TNFa, TNFy and GM-CSF levels in colorectal
cancer patients, Vardy (2007) found that none of the cytokines were significantly
associated with either objective or subjective cognitive impairment. Physiological
changes occurring in the brain after receiving chemotherapy is another plausible cause of
cognitive impairment in cancer patients. When using neuro-imaging techniques to
explore the cerebral anatomy of patients who received chemotherapy in relation to
healthy controls, a reduction in gray matter was found throughout the brain, hippocampal
volume loss existed, and decreased metabolic activity in the frontal areas of the brains of
cancer survivors who received chemotherapy was found (Reminger et al., 2004; Saykin et
al., 2003; Silverman et al., 2003). Other research is exploring mechanisms of
chemotherapy-induced cognitive function in animal models, but has not yet shown similar
results in clinical research.
Potential confounders to chemotherapy-induced cognitive dysfunction
A cancer diagnosis and treatment has the ability to change a person's emotional and
psychological stability. However, studies suggest that the incidence of depression in
cancer patients range from being no different than those without cancer (Keating,
Norredam, Landrum, Huskamp, & Meara, 2005) to greater than forty percent, with the
greatest rates of psychiatric morbidity being found in those receiving palliative treatment
(Fallowfield, Ratcliffe, Jenkins, & Saul, 2001). Jenkins et al. (2006) found that patients
with early breast cancer who exhibited psychological distress, reported significantly more
cognitive failures. Within the oncologic literature, a significant correlation between
objective cognitive performance and depression or anxiety has not been found (Vardy,
Rourke, & Tannock, 2007).
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However, the relationships between cognitive changes and emotional distress, such
as anxiety or depression, have been extensively studied and reported outside of the
oncology literature. Relative to states of anxiety in case-control studies, cases were found
to have significant impairments in episodic memory and functioning over controls
(Airaksinen, Larsson, & Forsell, 2005) and more severe symptoms of anxiety were
negatively associated with cognitive function (Bierman, Comijs, Jonker, & Beekman,
2005). More extensively studied is the relationship between depressive states and
cognitive dysfunction. In their review of studies exploring cognitive deficits in
depression, Austin, Mitchell, and Goodwin (2001) found mnemonic deficits and
executive impairments occurred independently of age, or depression severity or subtype.
In case-control studies exploring depression and cognitive dysfunction, cases were
consistently found to perform worse in functions of memory, response suppression and
multi-tasking (Austin et al., 1999; Channon & Green, 1999) and impairments of memory
and executive function were found to continue despite remission of a depressive episode
(Rubinsztein, Michael, Paykel, & Sahakian, 2000). Therefore, it is important for studies
reviewing the causes of chemotherapy-induced cognitive dysfunction to consider a
variety of other factors apart from the chemotherapy treatment itself.
Cancer related fatigue exists and may last well beyond the treatment period (Tchen
et al., 2003). A strong association between fatigue and perceived cognitive impairment
has been found, but has not been evident when exploring fatigue and objective
neuropsychological testing (Ahles et al., 2002; Schagen et al., 1999; Tchen et al.; van
Dametal., 1998).
In most chemotherapy protocols, it is standard for other medications to be
prescribed in order to alleviate many of the unwanted side effects of chemotherapy.
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These medications are often steroid based, which on their own have been found to affect a
person's cognitive performance. Glucocorticosteroids have been shown to decrease
capillary permeability of the blood brain barrier and decrease cerebral blood flow (Saykin
et al., 2003). Newcomer, Craft, Hershey, Askins, and Bardgett (1994) conducted a four
day trial of double-blind, placebo controlled dexamethasone study in normal adults to
determine the impact of the treatment upon cognitive function. They found impairment
of verbal declarative memory performance after only a four day treatment of relatively
low-dose of dexamethasone. More recently, similar findings have been found in healthy
adults receiving hydrocortisone therapy (Newcomer et al., 1999). Collectively, these
studies should caution both clinicians and researchers to other potential contributors of
change in cognitive function.
The objective measurement of cognitive dysfunction
There are a number of tools available to measure changes in cognitive function.
Neuropsychologists recommend a comprehensive battery of tests to best assess cognitive
function, but vary in opinion of what tests, and how many (Vardy et al., 2007).
Therefore, the ideal method of measuring cognitive function would evaluate a number of
domains, be brief and non-stressful for patients, independent of language skills, free of
practice effects and sensitive to changes occurring over time (Robbins, James, Owen,
Sahakian, Mclnnes, & Rabbitt, 1994; Tannock et al., 2004; Vardy, 2005, Vardy et al.,
2007). A tool to evaluate cognitive function that contains all of the above characteristics
does not exist (Vardy, 2005), so the measurement of such functioning in research studies
is widely varied.
In their praised review of cognitive function and chemotherapy studies, Vardy et al.
(2007) found that studies are inconsistent in describing types of cognitive function,
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although the commonly affected domains include complex attention/concentration, verbal
and visual memory and processing speed. Since most neuropsychological tests report
their results as Z or T scores, a definition of cognitive dysfunction is commonly based on
the cutoff scores for the various tests. Within their review, Vardy et al. acknowledge that
subtle impairment is most commonly defined as greater than 1 SD below the mean, while
higher levels of dysfunction lie between 1.5 to 2 SD below the mean. It is also difficult to
precisely define cognitive impairment because batteries contain several individually
scored tests. That said, it is a common practice for impairment to be determined on more
than one test to classify a person as cognitively impaired. This results in a variable
objective definition of cognitive impairment which makes comparisons between studies
very difficult.
To overcome the problem of using multiple tests to define cognitive impairment,
Global Deficit Scores (GDS) are commonly used to define objective cognitive
impairment. Heaton et al. claim that the GDS considers both the number and severity of
deficits an individual performs on a battery of tests, while paying less attention to
performances that lie within and above normal limits (as cited in Carey et al., 2004). The
demographically corrected T-scores of individual tests are converted to a deficit rating,
ranging from 0 (no impairment) to 5 (severe impairment) (see Table 1). These ratings are
then averaged to create a Global Deficit Score (GDS) for the battery completed by each
participant (Carey et al., 2004). A GDS of greater than or equal to 0.5 means that a mild
impairment was averaged over 50% of the tests. Although a GDS of 0.5 has been
suggested as the cutoff for detecting cognitive dysfunction in HIV patients, no optimal
cutoff for cancer patients has been determined.
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Table 1: A Conversion Table for Transforming T-Scores into Deficit Scores
(Carey et al., 2004)
T-Score
Impairment
Deficit Score
Descriptor
>40
0
Normal
39-35
1
Mild
34-30
2
Mild to Moderate
29.25
3
Moderate
24-20
4
Moderate to Severe
<19
5
Severe

Within the oncology literature, the High Sensitivity Cognitive Screen (HSCS) has
been frequently used to measure and assess changes in cognitive function. Although
valid, reliable and sensitive to the detection of subtle cognitive impairment (Serper &
Allen, 2002), the HSCS has been recently found to have limitations within cancer
research. Such limitations include the acknowledgement of a practice effect with
repeated measures that may underestimate the level of cognitive dysfunction in patients as
compared to the initial evaluation (Mar Fan et al., 2005), and that the HSCS may not be
sensitive enough to detect subtle cognitive impairment (Vardy, 2005). Also a limiting
factor is the tool's inability to be used with participants with an inadequate knowledge of
the English language, since the recipients of care at urban cancer centres include many
people from non-English speaking cultures.
Another tool used to assess impairment in cognitive function is the Cambridge
Neuropsychological Test Automated Battery (CANTAB). Although not extensively used
within oncology research, the CANTAB batteries have been validated and used to assess
cognitive performance in a variety of neuropsychiatric disorders in comparison to healthy
controls (Lowe & Rabbitt, 1998; Luciana, 2003; Robbins et al., 1994). The main
advantage of the CANTAB is that it uses a touch-screen computer, which offers the
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research subject an unbiased and highly consistent mode of presentation, without
necessitating a strong command of the English language. It also has the advantage of
incorporating a wide variety of tests using both frontal and temporal functions (Lowe &
Rabbitt, 1998; Robbins et al., 1994). The CANTAB measures visual memory, working
memory and planning, sustained attention, motor skill, information processing and
recognition memory via the following tests: Motor Screening (MOT), Affective Go/NoGo (AGN), Big/Little Circle (BLC), Delayed Matching to Sample (DMS), Intra-Extra
Dimensional Set Shift (IED), Match to Sample Visual Search (MTS), Paired Associates
Learning (PAL), Pattern Recognition Memory (PRM), Reaction Time (RTI), Rapid
Visual Information Processing (RVP), Stockings of Cambridge (SOC), Spatial
Recognition Memory (SRM), Spatial Span (SSP), Spatial Working Memory (SWM), and
Verbal Recognition Memory (VRM) (Cambridge Cognition Limited, 2004). Further
details outlining these tests can be found in Appendix E. Although extremely
comprehensive and easily administered and completed, the CANTAB has limitations in
how long it takes to complete (2 hours 30 minutes in entirety), and requires the additional
costs of obtaining software, hardware and administrator training (Cambridge Cognition
Limited, 2004: Collie, Darby, & Maruff, 2001).
Studies of prevention and coping with chemotherapy-induced cognitive dysfunction
As previously outlined, the exact mechanisms of chemotherapy-induced cognitive
dysfunction are unclear. As such, there are a minimal number of reports that have studied
interventions to prevent or enable patients to cope with such cognitive dysfunction, and
those studies have failed to show strong results. For example, a study of breast cancer
patients receiving adjuvant or neoadjuvant chemotherapy were randomly assigned to
receive epoitin-a or standard treatment over the course of their chemotherapy treatment,
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and were compared for changes in cognitive function, quality of life and fatigue. When
cycle 4 treatment scores were compared to baseline, the epoitin-a group had a mean
change from 1.3 to -3.3 in their cognitive performance with the control group
demonstrating a smaller mean change of 0.3 to -2.4 (O'Shaughnessy, 2002;
O'Shaughnessy et al., 2005). Note is made that a negative change indicates improved
function, and that there were no changes in mean changes from baseline to the 6-month
assessment of cognitive function (O'Shaughnessy et al., 2005).
There is little anecdotal information found within the oncology literature to guide
practitioners in developing interventions to enable cancer patients to cope with cognitive
dysfunction. However, at a cognitive workshop, breast cancer survivors discussed the
cognitive problems following treatment as well as coping strategies employed (Tannock
et al., 2004). Such strategies include avoiding multiple simultaneous tasks, decreasing
workload and increasing rest periods. Other than this, little is known about the impact of
cognitive dysfunction upon the cancer patient. It is for these reasons that further studies
are necessary to understand this impact in order to guide practice, and to assist clients
through the development of holistically sensitive interventions.
Psychosocial Adjustment
A history of the term
In the mid-1900s, psychiatrists began to recognize a relationship between patients'
physical illness and their coping and social supports (Derogatis & Fleming, 1996). It was
in the 1950s that preliminary attempts were made to measure these relationships, which
was then termed psychosocial adjustment. Since that time, few psychometric instruments
have been developed to measure psychosocial adjustment despite the literature outlining
the strong psychosocial component that characterizes the etiology, course and outcome of
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chronic medical conditions, such as cancer (Derogatis & Derogatis, 1990; Derogatis &
Fleming, 1996).
Psychosocial adaptation or adjustment: What's the difference?
The terms psychosocial adaptation and psychosocial adjustment are both found in
the literature and are often used interchangeably. It is for this reason that a brief review
of these terms will be provided.
In relation to the person coping with a traumatic life event, Livneh and Antonak
(1997) describe psychosocial adaptation as a gradual process that assimilates the changes
occurring in the individual's body, body image, ego, self concept and person-environment
interactions. Within the process toward adaptation, adjustment is the clinical and
subjective final phase of the process, expressed in terms of reaching and maintaining
psychosocial equilibrium; achieving reintegration; striving to reach life goals; positive
self-esteem, self concept and self-regard; as well as experiencing a positive attitude
toward the self, others and one's disability (Livneh & Antonek, 1997).
In further reviewing the literature, there were no other definitions that clearly
segregate the meaning of adaptation from adjustment. Therefore, for the purposes of this
research, the term adjustment will be used herein and will be the concept of interest.
A varying definition
Upon reviewing the scholarly literature, it is evident that the concept of
psychosocial adjustment is used variably despite being studied for a number of years.
Friedman, Baer, Lewy Lane, and Smith (1988) identified that the definition and
measurement of psychosocial adjustment has been attempted in three ways: by using
clinical indicators such as mood states to infer psychosocial adjustment; by using the
behaviours correlated with mood states, such as sleeping or eating patterns, to infer
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psychosocial adjustment; and by measuring the impact of specific roles and relationships
as an implication of psychosocial adjustment.
There is consensus that psychosocial adjustment is a subjective, multi-dimensional
concept (Bishop, 2005; Derogatis & Fleming, 1996; Linveh & Antonak, 1997; Shapiro,
Lopez, Schwartz, Braden, & Kurker, 2001). Some research studies define the concept
using a variety of psychometric tools to collectively measure varying interpretations of
psychosocial adjustment. Such tools have included the measurement of the concepts of
subjective well-being, self-concept, coping, life goals and satisfaction, psychological
consequences such as depression, distress and worry, as well as inter-relational issues
such as communication problems, social support and role functioning (Carlsson,
Bjorvatn, Engebretsen, Berglund, & Natvig, 2004; Derogatis & Derogatis, 1990; FelderPuig et al., 1998; Heim, Valach, & Scaffher, 1997; Shapiro et al., 2001; Visser et al.,
2003).
Derogatis and Derogatis (1990) view the psychosocial adjustment concept as one
made up of intrapsychic processes, interactions between the person and other persons, as
well as interactions taking place between the person and their sociocultural environment.
These interactions are achieved by the roles he or she performs. Derogatis and Derogatis
believe that it is the efficiency of these roles that highly correlate with the person's
interpretation of their psychosocial adjustment.
Psychosocial adjustment is made up of many domains. The prominent domains
included in the term are those that are, or are related to, people's significant role
behaviours. Derogatis & Derogatis (1990) acknowledge that the person alone determines
which domains are the most important in one's life. To create an objective measure, the
authors undertook a combination of rational-deductive and empirical-analytic procedures,
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which identified seven principal domains proving to be highly relevant to adjustment to
illness. These domains include: Health Care Orientation (8-items), which addresses the
person's attitudes and expectancies about the illness and treatment; Vocational
Environment (6-items), which reflects the impact of the illness upon the person's work,
school and/or home; Domestic Environment (8-items), which assesses problems in
adaptation as experienced by the patient and family; Sexual Relationships (6-items),
which measures any illness-related changes in the quality of sexual functioning or
relationship; Extended Family Relationships (5-items), that measures any relational
disruptions in the extended family constellation; Social Environment (6-items), reflecting
the degree of impairment or constriction of the person's social and leisure activities; and
Psychological Distress (7-items), which measures any distressing thoughts or feelings that
the person may have in relation to the illness (Derogatis & Derogatis, 1990). These
domains are used within the Psychosocial Adjustment to Illness Scale, which attempts to
operationally measure a person's psychosocial adjustment to a chronic illness.
Based on Derogatis' seminal work within the area of psychosocial research, the
remaining portions of this literature review will focus on research that has used the
definitions and Psychosocial Adjustment to Illness Scale developed by Derogatis in
respect to people diagnosed with cancer, specifically colorectal cancer. A description of
the Psychosocial Adjustment to Illness Scale follows.
An operational definition of psychosocial adjustment
The Psychosocial Adjustment to Illness Scale (PAIS) was originally developed to
take place in a semi-structured interview. Due to this costly and inconvenient method, the
Psychosocial Adjustment to Illness Scale - Self Report Version (PAIS-SR) was
developed. The tool is comprised of 46 items and refers the participant to "the past 30
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days including today" (Derogatis, 1986). The questions are designed to assess the
characteristics of a person's adjustment in each of the seven previously described
domains of the tool. Although each subscale measures the degree of adjustment to one's
condition within the specific domain, it is not correlated with the others, but is largely
correlated with the total adjustment score (Derogatis & Fleming, 1996). Each item
corresponds to a four-point scale with higher ratings indicative of poorer adjustment
(Derogatis & Fleming, 1996). Scores can be obtained for adjustment in each of the seven
domains and/or for overall adjustment as determined by the total of all the sub-scales.
Derogatis and Derogatis (1990) have outlined the method of scoring the PAIS-SR
score and sub-scores. The PAIS-SR is scored by summing each of the seven domains and
converting them to standardized area T-scores. This is done by referring the raw scores to
a table of published norms. These standardized T-scores for the seven domains are
summed to generate the PAIS Total Score. Summation of domain T-scores was chosen
over raw scores to provide equal weighting of each domain in constructing the PAIS
Total Score. Derogatis and Derogatis (1990) suggest that "respondents with a PAIS Total
Score equivalent or greater than a T-score of 62 are positive for clinical levels of
maladjustment" (p. 33).
Derogatis (1986) summarized the reliability of his instrument from three of his own
research involvements. One of the samples involved a group of 89 people diagnosed with
lung cancer, about whom demographics are not readily available in the academic
literature. Although the overall coefficient for the scale is not stated, 5 of the 7 subscales
have a coefficient greater than .80, and all of the scales range between .12 and .93
(Derogatis, 1986; Derogatis & Fleming, 1996). Both Derogatis and Derogatis and
Fleming comment that the Extended Family subscale, with a coefficient of .12, has been
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revised with the addition of a new item as well as other revisions. No comments are
made about the internal consistency of that new subscale.
In her dissertation research exploring the relationships between psychosocial
adjustment, social support and quality of life in adult colorectal cancer patients, Kelman
(1995) addressed the psychometric properties of the PAIS-SR as part of her sub-analysis.
She found an alpha reliability of .81 for the entire sample and .84 and .78 for men and
women respectively.
Merluzzi & Martinez Sanchez (1997) conducted a principal axis factor analysis of
the PAIS-SR in a sample of 502 adults with numerous types of cancer. This sample was
predominantly people with breast cancer (47%), with colorectal cancer comprising 8% of
the sample. The majority (72%) of participants in this study received chemotherapy as
part of their treatment, and 49% of the subjects were diagnosed less than a year prior to
entrance in the study. The entire PAIS-SR resulted with a coefficient alpha of .93, with
the original subscales ranging from .50 to .87, five of which were over .80. The scales
derived from the factor analysis yielded slightly higher coefficients.
Merluzzi and Martinez Sanchez (1997) report on the highly overlapping factor
structure with the original scales of the PAIS-SR. In fact, correlations between the seven
original scales and the seven-factor solution ranged from .82 - .99, with four of the scales
correlating higher than .90, and one being unreported by the authors (Merluzzi &
Martinez Sanchez, 1997). Their study also showed correlations of the subscales with
other measures of adjustment to illness, disease impact and coping, which further
supports the validity of the PAIS-SR for use in cancer research.
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The cancer diagnosis and psychosocial adjustment
Only a small number of studies have been conducted to explore the impact of
psychosocial distress upon cancer patients. Both Derogatis and Derogatis (1990) and
Wolberg et al. (1989) have illustrated that the cancer diagnosis alone contributes to a
statistically significant poorer adjustment, in comparison to those who screen negative for
a cancer diagnosis. Studies reviewing the magnitude of psychosocial adjustment in
cancer patients have found that 20-30% of heterogeneous cancer patients (Greer, 1994;
Harrison & Maguire, 1994), and as many as 38% of women diagnosed with breast cancer
(de Paula Lima, 2005) experience moderate to high levels of psychosocial maladjustment.
Therefore, just being given a cancer diagnosis affects a person's psychosocial adjustment,
irrespective of treatments or symptoms.
Local cancer treatments and psychosocial adjustment
Herranz and Gavilan (1999) attempted to determine the impact that two types of
surgery had upon the laryngeal cancer patient's psychosocial adjustment. Patients either
had radical surgery, in which all or nearly all of the larynx was removed, or functional
surgery, which was more conservative and preserved laryngeal function. In determining
the impact of radical or functional surgery upon the laryngeal cancer patient's
psychosocial adjustment, Herranz and Gavilan (1999) found statistically non-significant
differences between the groups. However, when comparing the global T scores for these
surgical groups, the radical group (56.92) showed slightly worse adjustment than the
functional group (56.44), in comparison to the reference cancer patient's group, whose
global T score was 50. Similarly, in her study comparing women with breast cancer who
had breast-conserving surgery or mastectomy, Hoskins (1997) found non-significant
differences between the groups on the Psychological Distress scale of the PAIS at three
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assessments during the first year after surgery. The mean of the Psychological Distress
scale for the entire sample, regardless of surgery, was found to be moderate at 13.10
(possible range = 0-28, alpha 0.89). However, both treatment groups' psychological
distress scores significantly improved over the course of the year. Residual disturbances
in psychosocial adjustment were found by Wolberg et al. (1989) in women up to 16months after having breast cancer surgery. Collectively, these studies could indicate that
cancer surgery, regardless of how extensive or disfiguring, comparatively affect the
cancer patient. The magnitude that these treatments have upon the cancer patient's
psychosocial adjustment is moderate and is likely to improve over an uncertain period.
Psychosocial adjustment has also been explored in relation to radiation therapy as
a treatment for cancer. Hassey Dow & Lafferty (2000) assessed the pre- and posttreatment psychosocial adjustment scores for women receiving radiation treatment for
early-stage breast cancer. Again, only moderate scores of psychosocial maladjustment
were found in this sample, but a statistically significant improvement in psychosocial
adjustment scores were found to occur in the time between beginning and ending
treatment, showing that localized cancer treatments are comparable in how they affect the
cancer patient's psychosocial adjustment.
Systemic cancer treatments and psychosocial adjustment
Hoskins' (1997) comparison of the Psychological Distress subscale of the PAISSR in breast cancer patients receiving either chemotherapy or not, failed to find a
statistically significant difference between these groups at either one or two months posttreatment initiation (at a comparable time point for the non-chemotherapy group).
However, a significant difference was found at 3-months, and again at six months after
treatment initiation. Hoskins' (1997) study clearly shows the differences between cancer

patients receiving systemic treatment or not and suggest that adjustment is a process
occurring over time.
Another study addressing chemotherapy and adjustment found significantly
poorer adjustment on five of the seven PAIS domains in a group of patients who
withdrew from chemotherapy treatment in comparison to those who completed standard
treatment (Gilbar & De-Nour, 1989). The reasons that patients refused to continue on
their treatment are not clear within the article outlining the study. However, Gilbar and
De-Nour (1989) do highlight that neither group's scores were high enough to be a sign of
psychosocial maladjustment, as indicated by the tool developer. This finding contradicts
that previously presented by Hoskins (1997) thus necessitating further research into
relationships between chemotherapy treatments and psychosocial adjustment.
Potential confounders to psychosocial adjustment in cancer patients
Factors other than a cancer diagnosis or treatment may also affect the cancer
patient's psychosocial adjustment. In her study exploring the factors contributing to
adjustment and quality of life in women diagnosed with cancer, Noukki (2000) outlined
the strongest predictors of poorer psychosocial adjustment. These included having less
social support, attributing the cause of the illness to bad-luck or self blame, holding back
on what one wants to do as a result of the illness, attributing control over the illness to
chance and finding less positive meaning out of the illness experience. While the
characteristics of disease treatment are not known to the reader, time since diagnosis was
a major variable within the analyses.
Psychosocial adjustment and colorectal cancer
Most of the studies assessing psychosocial adjustment in colorectal cancer
patients, have compared the adjustment scales of those who did to those who did not have
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stoma-related surgery. Although Canadian statistics on the incidence of colorectal cancer
related stomas are unknown, the American Cancer Society estimates that 1 in 8
Americans diagnosed with rectal cancer require a permanent colostomy as part of their
cancer treatment (2005). Compared to non-stoma bowel surgeries, stomal surgery in a
combined sample of malignant and benign colorectal diseases appears to increase the
incidence of psychosocial difficulties during the first four post-operative months
(Bekkers, van Knippenberg, van den Borne, & van Berge Henegouwen, 1996).
Specifically related to those who have a colostomy related to colorectal cancer, Kelman
(1997) found that 10% of women and 7% of men have been found to have positive
clinical levels of psychosocial maladjustment one year after diagnosis.
Nishigaki and colleages (2007) sought to explore the influence of life stage,
seniors (aged > 65 years) to non-seniors (age < 65 years), upon the psychosocial
adjustment of colorectal cancer patients without stomas (n = 93). They used the Japanese
version of the Psychosocial Adjustment to Illness Scale - Self Report, which uses 6 of the
7 domains of the original PAIS-SR, omitting the Health Care Orientation subscale. It is
not clear as to why these tools vary. Nishigaki's team (2007) conducted a multiple
regression analysis, treating each subscale of the PAIS-SR as a dependent variable and
background factors, such as years of education, marital status and occupation, as
explanatory variables. They found that Psychological Distress was the only domain that
differed between the two life stages, with seniors exhibiting less psychological distress
than the non-seniors (44.7 ± 7.7 and 48.6 ± 9.4, mean and standard deviation
respectively). The other five domains did not differ significantly between the groups and
total PAIS-SR scores were not analyzed as the entire original version was not used. This
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analysis outlined differences between the two life stages for each of the PAIS-SR
subscales.
In their study of colon cancer patients' adjustment scores during the first year after
surgery, Northouse, Mood, Templin, Mellon, and George (2000) found that men and
women follow a similar trend: low at diagnosis, reaching the highest point at two months,
and then declining to near-baseline scores at one-year, although women had slightly
lower scores than baseline. Alternatively stated, patients experienced more problems
with adjustment during their chemotherapy treatments before improving to near baseline
levels. In looking at the measures of adjustment, Northouse and colleagues (2000) found
significant correlations among the PAIS scores at all three time points: between baseline
and 2-months, baseline and lyear, and 2 months and 1 year. Both of these studies
illustrate the general trend of psychosocial adjustment in colorectal cancer patients during
the first year after diagnosis and surgery, indicating the importance of psychosocial care
received from their health care practitioners.
Nishogaki (2007) also explored the period since diagnosis in relation to the PAISSR subscales. The duration since diagnosis significantly contributed to the seniors'
maladjustment in the Social Environment Domain only. Whereas, only the Vocational
Environment Domain was significantly impaired by the time since diagnosis in the nonseniors group. Collectively, these studies illustrate that there are disturbances in the
psychosocial adjustment of colorectal cancer patients that vary over time and are related
to situation and background factors. This indicates the importance of the health care team
in monitoring a cancer patient's psychosocial adjustment and it's components.
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Psychosocial adjustment and cancer outcomes
Few studies have addressed the impact of psychosocial interventions on disease
outcomes of people diagnosed with cancer. In a review of the literature, Walker, Heys,
and Eremin (1999) comment on the accumulating evidence that psychosocial
interventions play in improving cancer patients' quality of life and prolonging their
survival. Outside of their review is a randomized controlled trial identifying the impact
that counseling and support interventions have upon patients' psychosocial adjustment.
Cain, Kohorn, Quinlan, Latimer, and Schwartz (1986) randomized women recently
diagnosed with gynecological cancer to receive individual counseling, group counseling
or standard care. Using the PAIS to measure psychosocial adjustment, Cain and her
colleagues found no significant differences in the women's baseline results, but found
that women who completed the individual or group counseling had significantly
improved adjustment 6 months after the intervention.
In terms of cancer survival, Goodwin et al. (2004) found no association between
early-stage breast cancer patients' overall medical outcome and their psychosocial status
at either diagnosis or 1-year. Although the study of psychosocial interventions' outcomes
are minimal, and show statistically weak and varying results, practitioners should be
cognizant of the impact that attention to psychosocial needs has upon their patients'
overall satisfaction with the professional care they receive (Walker et aL, 2003).
Quality of Life
Toward a definition of quality of life, as related to the oncology literature
Through the 1970s, as cancer treatments began to become more successful and
patients were living longer after a cancer diagnosis, more attention was directed toward
quality of life. A clear definition of quality of life remains elusive, however, it is
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generally agreed that it is a subjective, unique, multi-dimensional concept (Giesler, 2000).
In an attempt to define the concept of quality of life in relation to oncology, Cella
and Tulsky (1993) acknowledged the centrality of subjectivity in determining one's
quality of life. They proposed that quality of life be defined as "patients' appraisal of and
satisfaction with their current level of functioning compared to what they perceive to be
possible or ideal" (Cella & Tulsky, 1993).
Factor analyses and scale aggregation studies (Cella, 1992) have supported the
validity of four primary dimensions of quality of life: physical, functional, emotional and
social. The physical dimension refers to the person's perceived and observed bodily
function as related to disease symptoms or treatment side effects. Functional well-being
refers to the person's ability to perform activities of daily living, and actions that meet
one's ambitions and social roles. A person's emotional well-being is related but distinct
from their physical well-being and may reflect a positive or negative affect. Lastly, the
social dimension includes one's perceived social support, maintenance of leisure
activities and family functioning. These dimensions serve to guide the measurement of
quality of life from the patient's perspective as it is important to assess one's needs,
evaluate treatment outcomes and predict responses to further treatment (Cella, 1992).
Measurement of quality of life in the oncology literature
A number of tools have been developed to measure quality of life, but two are
predominant within the oncology literature: the European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30 and the Functional Assessment of Cancer
Therapy - General Scale (FACT-G) (Holzner et al., 2006).
The EORTC QLQ-30 is a 30-item questionnaire made up of multi-item scales and
single items that reflect what the EORTC unclearly defines as a multi-dimensional quality
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of life (Aaronson et al., 1993). The nine multi-item scales include five functional scales
(physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and
nausea and vomiting), and a global health and quality of life scale. The remaining single
item questions address issues common among cancer patients such as dyspnea, loss of
appetite, sleep disturbance, diarrhea, constipation and disease/treatment financial impacts.
The tool has been found to be reliable and valid (Aaronson et al., 1993).
The FACT-G arose from an attempt to develop a brief, valid and reliable tool to
measure general quality of life in patients receiving cancer treatment. Cella, Tulsky, Gray
and colleagues (1993) undertook a five-phase validation process involving 854 patients
with cancer and 15 oncology specialists. After an initial pool of patients and
professionals completed an open-ended interview, items were overlapped and then further
reduced to compile a version containing 38 items. After factor and scaling analyses of
this initial version with a large population of patients with mixed cancer diagnoses, a final
version of the FACT-G was developed. The result, a 27-item highly reliable, valid and
sensitive tool, available in numerous languages, and has been widely used in
heterogeneous cancer populations in an array of research studies and clinical trials.
In 2006, Holzner and colleages sought out to equate the EORTC QLQ-C30 and
FACT-G using classical test theory and the Rasch measurement model. In addition to
collecting sociodemographic data, each of the measures were given to a sample of
heterogeneous cancer patients (n=737), 362 (49%) who completed the EORTC-QLQ-C30
first and 375 (51%) who completed the FACT-G first. The data analysis showed that
three of the tools' domains were equatable: the physical, emotional, and functional/role
domains. Discrepancies were found for the social domains of the tools. As such,
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conversion tables were constructed for the 3 domains that were comparable which will be
useful for future quality of life meta-analyses, translations and interpretations.
Functional Assessment to Cancer Therapy - General (FACT-G)
It is the FACT-G that will be used to further explore quality of life in the cancer
related literature. The core questionnaire (Version 4) assesses 4 domains and employs
Likert-type questions ranging from 0 ('not at all') to 4 ('very much'). The domains and
ranges of scores for each are as follows: Physical Well-Being (PWB) (7-items, range 028), Social/Family Well-Being SFWB) (7-items, range 0-28), Emotional Well-Being
(EWB) (6-items, range 0-24) and Functional Well-Being (FWB) (7-items, range 0-28)
(Cella, Hahn, & Dineen, 2002). The total FACT-G score is the sum of the four subscales
(range 0-108), and is computed if greater than 80% of the items have a response (Brucker,
Yost, Cashy, Webster, & Cella, 2005). Higher overall scores are associated with
increased satisfaction with quality of life. Normative data for general and cancer patient
populations are available (Brucker et al., 2005).
Quality of life, cancer, and treatment-related side-effects
Quality of life has been studied in relation to cancer diagnoses, treatments and sideeffects. Studies of heterogeneous groups of cancer patients have found that disease
symptoms and psychological variables have explained as much as 44% of the variance of
quality of life. For example, in their prospective study determining the rates and course
of emotional distress, cognitive function and quality of life in cancer patients treated with
chemotherapy, Iconomou et al. (2004) found that at the end of treatment, depression was
the sole predictor of quality of life, explaining 44% of the variance. Similarly, Redeker et
al., (2000) found through a hierarchical regression analysis, that depression and anxiety
explained 43% of the variance in quality of life. Other disease and treatment side-effects
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that have been negatively correlated with quality of life include gender, fatigue,
menopausal symptoms induced by chemotherapy, receiving current treatment, insomnia,
depression and anxiety (Parker, Baile, De Moor, & Cohen, 2003; Redeker et al., 2000;
Tchen et al., 2003).
Quality of life, cancer stage and treatment
Measures of quality of life have not been found to be associated with medical
outcomes, specifically for women with early-stage breast cancer (Goodwin et al., 2004).
In fact, studies of quality of life in relation to cancer treatment have found an initial
decrease in overall quality of life within the first few months after diagnosis (Visser et al.,
2003; Hassey Dow & Lafferty, 2000), while longitudinal studies find these levels return
to baseline levels within 6 months after treatment is completed (Hassey Dow & Lafferty,
2000). More discriminating studies have found that the type of treatment administered,
specifically chemotherapy, significantly impacted the cancer patient's quality of life as
compared to other cancer treatments (Ahles et al., 2005; Jenkins et al., 2006).
The literature has shown varying results when looking at quality of life (FACT-G)
in relation to the stage of cancer. Specifically related to chemotherapy treatments,
Iconomou et al. (2004) found that patients scheduled to receive first-line metastatic
chemotherapy reported a significantly poorer quality of life compared to those
commencing adjuvant chemotherapy.
Although destined to determine age-related differences in quality of life in cancer
patients, the sample collected by Mkanta, Chumbler, Richardson, & Kobb (2007) was
largely comprised of late-stage (2/3) cancer patients (91 %) undergoing 6-months of
chemotherapy. They found that tumour stage and performance status were not
significantly related to quality of life. In fact, among the older adults (> 65 years), the
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unadjusted mean of the overall quality of life score was found to increase over the 6month treatment period.
In their study documenting quality of life, symptom distress and performance status,
Hwang, Chang, Fairclough, Cogswell, & Kasimis (2003) assessed 67 advanced cancer
patients at 3-6 week intervals from the time of no active anti-cancer treatment to their
death. They found that overall quality of life scores steadily deteriorated from 6 months
prior to death, with a rapid decline occurring in the final 2-3 months prior to death.
Correlations between performance status and overall quality of life were significantly
correlated at 2 to 6 months before death, but no such correlation was found in the last 2
months of life with any of the quality of life sub-scales.
Although these studies indicated opposing results for the quality of life in advanced
cancer patients, the differences may be attributed to treatment and imminent disease
prognosis.
Quality of life and colorectal cancer
Studies have been done to investigate issues related to quality of life from the
perspective of the patient living with colorectal cancer. Although some issues related to
the colorectal cancer patient's quality of life appear to be similar to the larger,
heterogeneous cancer population, these patients do have some quality of life issues that
are unique to them and have resulted in poorer overall quality of life scores (Mkanta et
al., 2007). These factors include pain, constipation, fatigue, diarrhea and non-cancer
chronic health problems (Arndt, Merx, Stegmaier, Ziegler, & Brenner, 2004; Cameron,
2005; Esnaola et al., 2002; Rauch, Miny, Conroy, Neyton, & Guillemin, 2004; TrenthamDietz et al., 2003).
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In their randomized study assessing the relationship between the type of colorectal
surgery and quality of life, Weeks, Nelson, Gelber, Sargent, and Schroeder (2002) found
that for up to two months post-operatively, quality of life was unrelated to whether
patients-had undergone laparoscopic surgery or an open colectomy. Alternatively, a
systemic review within the Cochrane Database claimed that varying study findings made
it impossible to make firm conclusions relating stoma-producing surgery with quality of
life (Pachlar & Wille-Jorgensen, 2005).
In her longitudinal, cohort study, Vardy (2007) noted that 23% of patients had a
decline in overall quality of life from pre- to post-chemotherapy assessments, whereas
there were no declines seen in the control group for this time period. These findings
failed to reach statistical significance.
These findings collectively illustrate the need for further studies assessing the
quality of life from the perspectives of patients living with colorectal cancer.
Cognitive Dysfunction, Psychosocial Adjustment and Quality of Life
As outlined in the previous sections, cognitive function related to cancer and its
treatments have been understudied, while quality of life related to cancer and its
treatments has received a significant amount of attention in the academic literature. There
is also very little research relating the cognitive dysfunction that cancer patients
experience to their quality of life. Iconomou et al. (2004) explored the relationship
between cognitive performance, as determined by the Mini-Mental State Examination
(MMSE), and global quality of life, as determined by the European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30, in a group of heterogeneous
cancer patients completing chemotherapy. They found that the participants' scores on the
MMSE had a small, negative, although non-significant, correlation with global quality of
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life. However, when exploring the participants' perception of their cognitive dysfunction,
as determined by the Cognitive Subscale of the EORTC-QLQ30, the researchers found a
statistically significant positive correlation with global quality of life. From this study, it
is clear that quality of life is impacted by one's perception of a poorer cognitive function
rather than by an actual impairment in function. Similar studies of women receiving
chemotherapy for breast cancer have also found no statistical association between
objective cognitive function scores and quality of life (Tchen et al., 2003; Brezden et al.,
2000), but acknowledge the small incidence of cognitive dysfunction resulting from
chemotherapy results in a small sample size having insufficient power to make definitive
conclusions (Tchen et al.).
In their review of the literature, Desai, Butt, Sabatino, and Wagner (2005)
acknowledge that although cognitive dysfunction has been demonstrated in cancer
patients receiving chemotherapy through neuropsychological and patient self-report, there
have not been validated instruments to assess self-reported cognitive dysfunction. The
authors decided to address this gap by developing and validating a cancer-specific selfreport tool to assess cognitive impairments and the impact of these impairments on the
patient's quality of life. Using information gathered from interview and focus groups in
which patients said that cognitive impairments impacted their quality of life and
functional status, a thematic content analysis resulted in a Functional Assessment of
Cancer Therapy-Cognitive subscale (FACT-Cog). Further studies using the FACT-Cog
have found it to be a reliable and valid tool which has demonstrated higher internal
consistency reliability and convergent validity than other comparable tools within
oncology research (Jacobs, Jacobsen, Booth-Jones, & Wagner, 2004). Collectively these
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studies show the increasing recognition of the relationship between cognitive function
and quality of life in cancer patients.
Psychosocial Adjustment and Quality of Life
In using the previously mentioned definition of psychosocial adjustment
developed by Derogatis and Derogatis (1990), very little has been found within the
scholarly literature to relate the concepts of psychosocial adjustment and quality of life.
In a longitudinal study examining quality of life and psychosocial adjustment in breast
cancer patients receiving radiation, results fail to show any significant differences in
psychosocial adjustment or quality of life from the beginning to conclusion of treatment
therapy (Hassey Dow & Lafferty, 2000). Although the two concepts were not examined
for correlations with each other, the trend in their overall scores failed to show significant
differences between the two concepts at the same time points of the disease/treatment
trajectory. In his case-control, quasi-experimental study, Batton (2000) found a
statistically significant correlation between pre-test and post-test scores of the PAIS and
quality of life in a group of heterogeneous cancer patients. Specifically related to
colorectal cancer patients, Kelman's (1997) study of the relationships between
psychosocial adjustment and quality of life found a significant relationship for the total
sample, as well as between men and women. These studies concur about this inverse
relationship indicating that those who report fewer problems with adjustment report a
higher quality of life. In further relating these concepts, Kelman (1997) used a multiple
regression analysis to find that approximately 18% of the variance in quality of life was
accounted for by psychosocial adjustment in the total sample, and 23% and 19% for men
and women respectively. These results illustrate the relationship between quality of life
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and psychosocial adjustment indicating that those who report fewer adjustment problems
report a hi gher quality of li fe.
Summary of the literature
In summary, there is insufficient exploration relating psychosocial adjustment as
defined by Derogatis and Derogatis (1990) to quality of life (as defined using the FACTG), although the concepts have been thoroughly studied individually. There is a paucity
of research that has related cognitive dysfunction to quality of life, and even less that has
explored how cognitive dysfunction impacts the cancer patient's psychosocial adjustment.
Therefore, the purposes of this research are: (a) to clarify the relationship between the
concepts of psychosocial adjustment and quality of life, and (b) to gain further
understanding of how chemotherapy-induced cognitive dysfunction impacts these
concepts in relation to the experience of living with colorectal cancer.
Research Questions
1. What impact does adjuvant chemotherapy-induced cognitive dysfunction have
upon the colorectal cancer patient's psychosocial adjustment?
2. Does psychosocial adjustment differ between people diagnosed with colorectal
cancer who do and do not receive adjuvant chemotherapy?
3. What is the relationship between psychosocial adjustment and quality of life
within a sample of colorectal cancer patients?
Chapter III
Methodology
Study Design
A descriptive, correlational design was used to explore the relationships between
cognitive dysfunction and psychosocial adjustment, as well as psychosocial adjustment
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and quality of life in adults diagnosed with non-metastatic colorectal cancer. The sample
was recruited from a larger, prospective, longitudinal cohort study of cognitive function,
fatigue and quality of life in patients with localized colorectal cancer.
Study Population
Patients with histologically confirmed stage A, B or C colorectal cancer, who had
undergone surgical resection, were eligible to participate in this study. The sample
consisted of 4 groups: Groups A & C (stage III/ high-risk II disease), with Group A
assessed pre-chemotherapy and Group C post-chemotherapy; while Groups B & D (stage
I/II disease) included those that did not require chemotherapy, with Group B assessed
post-operatively and Group D assessed 6-months post-operatively.
All participants were 18-75 years of age; had an ECOG performance score of 0
(fully active, able to carry on all pre-disease performance without restriction) or 1
(restricted in physically strenuous activity but ambulatory and able to carry out work of a
light or sedentary nature) (Eastern Oncology Cooperative Group, n.d.); had a life
expectancy of at least 12 months; and had adequate hepatic function documented by a
serum bilirubin < 18 umol/L and liver function tests within 1.5 times normal range.
The criteria for the study excluded those with any major pre-existing psychiatric
history or dementia, alcohol abuse, or those using psychotropic medication that might
lead to cognitive problems, other than short acting benzodiazepines for nausea or sleep.
Patients with a pre-existing neurological condition that was likely to interfere with their
ability to perform cognitive testing were also excluded. Other exclusion criteria included
evidence of metastatic disease; ongoing sepsis, or uncontrolled or HIV infection; other
severe co-morbidity making participation inappropriate to this study; active cancer within
the past 5 years; previous history of chemotherapy; and minimal English skills such that
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subjects would not be able to follow simple written English instructions and to read
questionnaires of a grade 8 standard with the help of a research assistant.
The study was initiated with participants being recruited from eight hospitals in
Toronto. Due to difficulties in obtaining the projected sample size, permission was
granted to expand the study into two hospitals in Sydney, Australia, where the larger
study was in operation. This action was deemed acceptable due to the similarities in
demographic of these countries. Each institution's Research Ethics Board approved the
study, and all participants gave written informed consent.
Sample Size
A moderately strong association between the variables of interest was defined as
present if the Pearson correlation coefficient was 0.35 or higher (this is equivalently
found when using a linear regression model with only one predictor variable). To test the
null hypothesis (HO: r = 0) versus the alternative hypothesis (HA: r = 0.35), with an alpha
= 0.05 and 80% power, a total sample size of 64 patients was required. Thus, the aim was
to accrue 16 patients to each of the four treatment groups, which gave sufficient power to
detect moderately strong associations. It was determined that if the relationship between
cognitive ability and psychosocial adjustment were different between the groups, then the
association would be estimated for each treatment group individually. In this situation,
sufficient power was still present to detect a strong relationship (alpha = 0.05, power =
80% to detect a correlation of 0.64).
Data Collection Procedures
In the larger prospective, longitudinal study, participants completed a series of
assessments in the following order: traditional neuropsychological tests; four batteries
from the Cambridge Neuropsychological Test Automated Battery (CANTAB); the
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Functional Assessment of Cancer Therapy - Cognition (FACT-Cog); the Functional
Assessment of Cancer Therapy - General (FACT-G); the Functional Assessment of
Cancer Therapy - Fatigue (FACT-F); the General Health Questionnaire (GHQ); and a
series of laboratory tests. These assessments were conducted at baseline (either prior to
chemotherapy administration for the cases, or within 12 weeks of surgery for the control
group), and afterward at 6,12 and 24 months.
For the purposes of this smaller correlational study, subjects were approached for
participation at their baseline and 6-month assessment within the larger study (refer to
Appendix A for the study schemata). At only one of these assessments were the subjects
approached by the researcher to discuss this study's objectives and requirements. If
subjects were agreeable, they were given a package containing an Informed Consent
Form, the Psychosocial Adjustment to Illness Scale - Self Report Version (PAIS-SR) and
a return addressed, stamped envelope in which the completed consent form and PAIS-SR
was returned to the researcher. If a package was not returned within two weeks, the
researcher made a courtesy reminder call to the patient. A log was kept of each
distributed package for recruitment statistics.
The consent forms for this study identified that the CANTAB and questionnaire
scores would be retrieved from the larger study, should patients agree to participate in this
research. Therefore, by signing the consent form to participate in this study, participants
were agreeing to this retrieval.
Measurement Tools and Operational Definitions
Cambridge Neuropsychological Test Automated Battery (CANTAB)
The CANTAB has been assessed for both reliability and validity. Of concern in
longitudinal studies exploring cognitive function is the test/re-test reliability, which the
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CANTAB has been shown to be highly acceptable (r = 0.75-0.80) (Lowe & Rabbitt,
1998). The tool has also been validated through a factor analysis with varimax rotation in
a large sample of healthy individuals (Robbins et al., 1994). Together these results
appreciate the use of the CANTAB within research on cognitive function.
Due to the previously mentioned time taken to complete the entire battery, four tests
were selected to assess the most common domains assessed in cognitive function: the
Motor Screening test (MOT), the Reaction Time test (RTI), the Rapid Visual Information
Processing test (RVP), and the Spatial Working Memory test (SWM). For exploratory
purposes, a Total Reaction Time (TRI) score was calculated using the MOT reaction time
and the RVP reaction time. Also for exploratory purposes, a Problem Solving Speed
Measures (PSSM) score was calculated using the Five Choice Movement and Reaction
Times of the RTI, in addition to the SWM latency.
Z-scores were used to gauge cognitive performance within this study. The tests
used from the CANTAB provided demographieally corrected Z-scores for each test, with
a higher score indicating better performance.
Also of interest, were Global Deficit Scores (GDS) that were used to define
cognitive impairment. Cognitive impairment was defined by a GDS of >0.5, which has
been shown to provide an optimal balance between specificity (0.89) and sensitivity
(0.39) (Carey et al., 2004). As stated in preceding sections, GDS's are commonly
calculated using demographieally corrected T-scores, whereas the CANTAB reports Zscores for each test. Therefore, the CANTAB Z-scores were converted to T-scores using
a table developed by Anderson (personal communication, October 10, 2008), which then
allowed for GDS's to be determined. Anderson's conversion table is summarized in
Table 2, along with the Deficit Scores as outlined by Carey et al. (2004).
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Table 2: A Table Relating T-Scores and Z-Scores to Global Deficit Scores
Impairment
"1-Score
/-Score
Deficit Score
Descriptor
0
Normal
>40
> 0.99
39-35
1
Mild
-1.0--1.49
2
34-30
-1.5--1.99
Mild to Moderate
29-25
-2.0 - -2.49
3
Moderate
4
24-20
-2.5 - -2.99
Moderate to Severe
<19
<-3.0
5
Severe

Psychosocial Adjustment to Illness Scale - Self-Report Version (PAIS-SR)
The PAIS-SR (Derogatis, 1990) is a useful tool for assessing subject's overall
adjustment to illness, as well as their adjustment to a number of domains of psychosocial
adjustment. The internal consistency reliability of the entire tool has been reported in a
number of oncology studies ranging from a Cronbach's alpha of 0i93 in heterogeneous
cancer samples (Merluzzi & Martinez Sanchez, 1997) to 0.81 in samples of people
diagnosed with colorectal cancer (Kelman, 1997). Factor structure and correlations with
disease impact, adjustment and coping, all support the validity of the PAIS-SR and its use
within the oncology research (Derogatis & Fleming, 1996; Merluzzi & Martinez Sanchez,
1997).
Therefore, the PAIS-SR has both reliable and valid strengths for usage within
oncology research and was used to measure the psychosocial adjustment in the current
research study. Although the Total PAIS-SR score was the variable of interest,
exploratory analyses individually investigated each of the seven domains of the tool.
Participants were asked to complete the 46 items representing the seven domains of
the PAIS-SR. Each domain score was converted to a standardized area T-score and
summed to generate a Total Score. A score of greater than or equal to 62 indicated
maladjustment, as indicated by Derogatis and Derogatis (1990).
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Functional Assessment of Cancer Therapy — General measure (FACT-G)
As outlined in the preceding sections, the FACT-G has been widely used within
cancer research. In studies of large, heterogeneous cancer samples, the FACT-G has
shown a high internal consistency reliability (a = 0.89) (Cella, Tulsky, et al., 1993;
Mkanta, et al, 2007) and high convergent validity (r = 0.79) with other quality of life
tools in the oncology literature (Cella, Tulsky, et al., 1993). For these reasons, the FACTG was determined to be an appropriate tool to assess quality of life in this sample. Again,
although the total FACT-G score was of primary interest, the four sub-scale scores were
explored individually.
Participants were asked to complete the 27 items representing the 4 subscales of the
FACT-G. The total FACT-G score, which is the sum of the scores for the four subscales,
was used to quantify quality of life (Brucker et al., 2005). A higher FACT-G score
indicates a higher quality of life.
Data Analysis
Once the data were collected, each measure was scored according to the
procedures identified by the developer. SAS version 9.1 was used for all statistical
analyses. Statistical significance was defined as a p-value of 0.05 or less and all tests
were two-tailed.
Descriptive statistics, such as the median, range, frequency and proportion were
used to summarize patient characteristics and study assessments. Medians and ranges
were the preferred methods of reporting due to the small numbers within treatment
groups. It is well known that the impact of an outlying result is greater upon the mean of
a small sample than that of a larger sample. For consistency, the medians and ranges of
both the treatment groups and the collective sample is reported.
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This cohort of patients was evaluated for comparability with the entire patient
cohort in the larger study by visual comparison. Data used as a measure for the entire
patient cohort were those used as part of a presentation at the American Society of
Clinical Oncology's Annual Meeting 2008. Comparisons of questionnaires between
groups were performed using the Kruskal-Wallis test for continuous outcomes and the potest for binary outcomes. Scores which had statistically significant differences between
groups, were further evaluated using pair-wise comparisons.
Linear regression methods were used to evaluate associations between
psychosocial adjustment, cognitive function, quality of life and the effect of patient group
on the associations. A regression model was constructed with psychosocial adjustment as
the outcome variable (measured by the PAIS-SR Total T-Score), and cognitive function
(measured by the CANTAB Z-score) as the predictor variable. The effect of patient group
was evaluated by including a factor for group and an interaction between cognitive
function and group. If neither the interaction variable nor the group factor was significant
as a predictor then the original model with only cognitive function was used. A similar
process was used to evaluate the association between psychosocial adjustment and quality
of life (measured by FACT-G). Level of association was estimated using the Pearson's
correlation coefficient and 95% confidence intervals calculated using Fisher's Z
transformation including the bias adjustment.
There was no multiple testing adjustment of the p-value, as the expectation was
that there would be only one primary outcome test (whether the association between
cognitive ability and psychosocial adjustment was significant across all patients). All
secondary evaluations were considered exploratory and p-values have been reported for
these tests.
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Chapter IV
Results
Sample Characteristics
Between February 1,2006 and June 30,2008,110 patients were approached to
participate in this study. Of those, four were excluded due to lack of informed consent,
one was excluded due to metastatic disease, five were excluded due to having previously
completed the PAIS-SR, and 26 did not return the study documents despite a courtesy
reminder call. This resulted in a sample size of 74 non-metastatic colorectal cancer
patients participating in this study.
It is important to note that five subjects were tested twice each. These participants
were approached during a time when study recruitment appeared to be slowing. The
analysis was re-run using only one evaluation per patient and using methods which
incorporate an assumed correlation for these subjects (i.e. generalized estimating
equations). Results were similar in all cases. Therefore, the analysis includes all
available data, including the participants who completed assessments twice, in attempt
increase the study's power.
Baseline demographic characteristics are presented in Table 3. This patient
sample was similar in age (median=61.0, range 23-75) and gender (39% female) as
compared with the patient demographics of the larger study (median age=58, range 23-75,
38% female).
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Table 3: Sample Characteristics
Characteristic"" • -' ••'- •'"' '•'" •
•
Cicnder
Male
Female
Marikil Status
Married/Common-Law
Separated/Divorced
Single
Widowed
Highest Level ofLducalion Achieved
Secondary
College/University
Post-Graduate
Alcohol Use (No. of drinks/day)
0
1
2+
Smoking Status
No
Yes
Ex
Psychiatric Drugs
No
Yes
Age

:

•' •:r.',£-*N^V
•
KJ •"Percentage'-'-5 v-.
45
29

60.8
39.2

51
6
10
1

75.0
8.8
14.7
1.5

18
35
14

26.9
52.2
20.9

30
26
7

47.6
41.3
11.1

40
3
25

54.8
4.1
34.3

55
6
74

90.2
9.8
61.0(23.6-75.9)
Median (range)

The majority of the sample were married or common-law, over half of the sample
had completed college or university, most drank none or little alcohol, and most were
non-smokers.
Table 4 outlines the disease stage and treatments for the study sample. The
majority of the case groups had had surgery where full staging was assessed. Four of the
cases were receiving neo-adjuvant chemotherapy prior to surgery so full staging was not
able to be determined at the time of the study assessment. For another 21 study

participants, their staging was undetermined. Since cancer stage was collected for
exploratory purposes only, these data were captured as "missing".
Table 4: Sample Treatment Characteristics
.I^KaipaE<eristi&^:r!^. ;-.:.*'- =-.
v:v"'>^*-* "•VVN*Y^ • Pejrceritage:.^::^
Cancer Stage
A
18
25.7
15
B
21.4
12
C
17.1
4
Neo-Adjuvant
5.7
21
30.0
Missing
Group
A(Pre-Chemo)
19
25.7
B (Post-Surgery Control)
18
24.3
C (Post-Chemo)
20
27.0
D (6-month Post-Surgery Control)
17
22.9
Chemotherapy Type (Groups A & C only)
5 Fluorouracil
1
3
5 Fluorouracil + Oxaliplatin
17
46
Capecitabine
2
5
Capecitabine + Oxaliplatin
1
3
5 Fluorouracil + Radiation
12
32
Missing
4
11
Cognitive Function
As expected, the CANTAB deficits seen in this group of patients were similar to
the larger study (25.0% vs. 22.0-29.0% respectively). No significant differences were
seen between the groups for either the CANTAB score or any of it's individual tests.
These results are displayed in Table 5.
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Table 5: Median (ranges) of CANTAB and Test Scores
1

"

-

(iroiip \

I oU

, - (I're-

''Sample
.•

-

* .

-

. .

-.

. •

. l hcmoj

1

C in nip B'
(I'oslSurjiL'rt'

GroupC

Conlrol)

Chcnio)

uroup L>. ... .- ."n j
(fi-Months
-Post-.,.Surgeiv,
Control J" \ : . • , . : • • •

N

64

16

13

20

15

CANTAB
Z-Score

-0.8
(-11.0,6.2)

-0.2
(-6.3,4.4)

-1.4
(-11.0,4.7)

-0.4
(-6.4,5.2)

-0.8
(-7.3,6.2)

0.94

MOT1
Z-Score

0.2
(-2.9,0.9)

0.1
(-0.8,0.9)

-0.1
(-2.9,0.8)

0.3
(-1.0,0.8)

0.2
(-1.4,0.8)

0.50

RTI1
Z-Score

-0.1
(-5.4,2.7)

-0.3
(-5.4,2.3)

-0.4
(-2.6,2.1)

0.1
(-3.3,1.9)

-0.0
(-5.0,2.7)

0.72

RVP1
Z-Score

0.2
(-3.3,3.1)

0.2
(-1.7,3.1)

0.1
(-3.0,2.3)

-0.3
(-3.3,2.8)

0.4
(-2.0,2.6)

0.64

SWM1
Z-Score

-0.6
(-3.1,3.5)

0.3
(-3.0,2.8)

-0.7
(-3.1,2.9)

-0.5
(-2.7,3.5)

-0.7
(-2.5,2.4)

0.89

TRI2
Z-Score

0.1
(-5.9,3.1)

0.2
(-1.9,2.9)

-0.4
(-5.9,3.1)

0.0
(-3.5,3.0)

0.5
(-1.8,3.1)

0.61

PSSM3
Z-Score
CANTAB
Deficits
N (%)

-0.5
(-5.8,5.0)

-0.7
(-5.3,2.5)

-0.5
(-5.1,3.2)

-0.3
(-5.6,5.0)

-0.4
(-5.8,4.2)

0.80

16(25.0)

6/16(37.5)

1/13 (7.7)

4/20 (20.0)

5/15 (33.3)

0.25

= Tests within the CANTAB: Motor Screening test (MOT); the Reaction Time test (RTI); the Rapid
Visual Information Processing test (RVP); and the Spatial Working Memory test (SWM).
2
= Total Reaction Time (TRI) computed using the MOT and RVP reaction times.
3
= Problem Solving Speed Measures (PSSM) computed using the RTFs Five Choice Movement and
Reaction Times as well as SWM latency.
4
= Applies only to the pair-wise comparisons of Groups A thru D. Does not include Total Sample results.

Psychosocial Adjustment
The Kruskal-Wallis test was used to explore differences between groups for the
PAIS-SR and it's subscales. These results are reported in Table 6. Significant
differences were found between groups, specifically the 6-month post-surgical control, in
terms of PAIS Total T-score (p=0.049). There was also a statistically significant
difference found for the Total T score when comparing the 6-months post-surgery control
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group and the post-chemo group (p=0.008), with the 6-months post-surgical control
showing better adjustment.
When exploring the group differences of the PAIS-SR subscales, significant
differences were found in terms of the Sexual Relations (SR) and Social Environment
(SE) subscales of the PAIS-SR (p<0.001 and p=0.010 respectively). When a statistically
significant difference between groups was observed for the Total T score, as well as the
PAIS-SR subscales, pairwise comparisons evaluated between each pair of groups using
least-squares means. Regarding the Sexual Relations (SR) subscale, the 6-months postsurgical control group was significantly better functioning than the post-chemotherapy
group (p<0.001) and the pre-chemotherapy group (p=0.001). Regarding the Social
Environment (SE) subscale, the 6-months post-surgery group was significantly better
functioning than the pre-chemotherapy group (p=0.033) and the post-chemotherapy group
(p=0.001). The post-chemotherapy and the post-surgical groups also significantly
differed (p-0.015), with the post-surgical group having higher functioning.

Table 6: Median (Ranges) for Total PAIS-SR and Subscale T-Scores
.Cinopp DU. -C': J « , .
Group B
CiroupV*" "(6-Months
Group \
1 otal
(IW.. (Prew fftbtr -•- !•--. Host-..* - r p-valije-^
Siirriplo
SurglT}
.C'hcmo)
Chcmo).
Control)
•

i -*

i

t

N

74

19

18

20

17

Total
T-Score

50
(23,75)

50
(23,75)

45
(23,70)

53
(34,75)

44
(23,63)

0.049

HCO
T-Score

48
(29,75)

48
(29,73)

47
(29,60)

48
(35,75)

46
(29,63)

0.32

VE
T-Score

57
(43,76)

62
(45,76)

56
(43,70)

56
(45,73)

52
(45,67)

0.089

DE
T-Score

42
(34,76)

49
(34,69)

44
(34,73)

47
(34,76)

39
(34,61)

0.10

SR
T-Score

53
(40,76)

53
(40,76)

51
(40,72)

56
(47,76)

43
(40,74)

<0.001

EFR
T-Score

46
(46,71)

46
(46,71)

46
(46,65)

52
(46,71)

46
(46,71)

0.45

SE
T-Score

47
(28,66)

49
(28,65)

46
(28,59)

51
(28,66)

45
(28,55)

0.010

PD
T-Score

46
(34,73)

46
(34,73)

48
(34,67)

46
(34,72)

44
(34,70)

0.94

= PAIS-SR domains: Health Care Orientation (HCO); Vocational Environment (VE); Domestic
Environment (DE); Sexual Relationships (SR); Extended Family Relationships (EFR); Social
Environment SE); and Psychological Distress (PD).
2
= Applies only to the pair-wise comparisons of Groups A thru D. Does not include Total Sample results.

Quality of Life
The FACT-G and subscale scores are reported for the total sample and groups in
Table 7. Differences between groups were compared for the FACT-G and subscales
using the Kruskal-Wallis test. The between-group differences in the global FACT-G
scores were statistically significant (p =0.028). More specifically, it was the postchemotherapy and 6-months post-surgery control groups' scores that significantly
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differed (p=0.010), with the 6-month post-surgical control having the higher quality of
life.
When comparing groups, significant differences were found in the scores of the
Physical Well-Being (PWB) and Social Weil-Being sub-scales (p-value = 0.037 and
0.042 respectfully). Within the Physical Well-Being subscale (PWB), the postchemotherapy group significantly differed from the pre-chemotherapy group (p=0.031)
and the 6-months post-surgical group (p=0.012), with the 6-month post-surgical controls
having the highest quality of life and the post-chemotherapy group having the lowest
quality of life. Within the Social Well-Being subscale, the post-chemotherapy group
differed from the 6-months post-surgical group (p=0.003), again with the 6-month postsurgical control group having the higher quality of life scores.
Table 7: Median (Ranges) for FACT-G and Subscale Scores
li>lal

Ciioup \

Ciroiip B
(PoMSurgcry •
Control)

Group C
(Po.sf-

(ft-Months '
I'ostp-valutj," .
Surgery f • • rf'tife
Contiol) ,

Sample

(IVChemo)

N

72

19

18

20

13

FACT-G

83.8
(36.1,100)

87
(36,98)

81
(59,98)

76
(43,95)

90
(56,100)

0.028

PWB1

90.5
(17.9,100)

96
(18,100)

89
(57,100)

80
(25,100)

93
(61,100)

0.037

SWBJ

85.7
(14.3,100)

86
(50,100)

86
(57,100)

81
(14,100)

96
(71,100)

0.042

EWB

87.5
(25.0,100)

85
(25,100)

83
(46,100)

85
(42,100)

92
(33,100)

0.69

FWB

75.0
(14.3,100)

79
(39,100)

75
(14,100)

68
(32,100)

89
(36,100)

0.16

ChaiKi)

1 = FACT-G subscales: Physical Well-Being (PWB); Social Well-Being (SWB); Emotional Well-Being
(EWB); and Functional Well- Being (FWB).
2 = Applies only to the pair-wise comparisons of Groups A thru D. Does not include Total Sample results.
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Research Questions
Potential associations between PAIS, CANTAB and FACT-G were evaluated
along with the effect of group. Using a linear regression model with PAIS total T score
as the outcome and CANTAB Z-score as the predictor, the interaction effect between
CANTAB Z-score and group was not significant (p = 0.56) nor was the effect of group as
a factor (p = 0.16). This process was repeated for each CANTAB subscale and neither
group nor interaction was a significant predictor of outcome for any subscale value.
Thus, one can infer that the effect on PAIS by CANTAB is unaffected by the patient
group.
Similarly, the association between PAIS total T score and FACT-G score is
unaffected by group when examined as part of an exploratory analysis (interaction p =
0.27 and group factor p = 0.31). As a result, associations between PAIS total T score with
CANTAB and FACT-G were evaluated after combining all patients into a single group.
Each score (PAIS, CANTAB and FACT-G) was approximately normal, thus, parametric
estimates are appropriate and the Pearson correlation coefficient was used to estimate the
association between these three factors. These results were used to answer Research
Questions 1 and 3.
1. What impact does adjuvant chemotherapy-induced cognitive dysfunction have
upon the colorectal cancer patient's psychosocial adjustment?
The Pearson correlation coefficient between PAIS Total T score and CANTAB Zscore was found to be -0.12 (95% confidence interval = -0.36 to 0.13, p = 0.33) (see
Figure 2). This result was not statistically significant. There was also no difference (p =
0.52 using a Wilcoxon ranksum test) in PAIS Total T score between those scored as
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having a deficit via CANTAB (mean score = 51.8) and those scored as not having a
global deficit via CANTAB (mean score = 48.8).

Figure 2: Association Between PAIS-SR and CANTAB
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2. Does psychosocial adjustment differ between people diagnosed with colorectal
cancer who do and do not receive adjuvant chemotherapy?
Significant differences were found between groups in terms of PAIS-SR total T
score (p = 0.049) and for the Sexual Relations (p < 0.001) and Social Environment (p =
0.010) subscales. Pair-wise comparisons found that the post-chemotherapy group
significantly differed from the 6-months post-surgical group in the PAIS-SR total T score
(p = 0.008), with the 6-month post-surgical controls having higher functioning. In terms
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of the Sexual Relations subscale, the 6-months post-surgical group had significantly
higher functioning than the pre-chemotherapy group (p = 0.001) and the postchemotherapy group (p < 0.001). In terms of the Social Environment subscale, the 6months post-surgical control group had significantly higher functioning than the prechemotherapy group (p = 0.033), and the post-chemotherapy group (p < 0.001), while the
post-chemotherapy had significantly poorer functioning than the post-surgical group (p =
0.015).
3. What is the relationship between psychosocial adjustment and quality of life
within a sample of colorectal cancer patients?
There was a significant correlation between the PAIS Total T score and the FACTG (r = -0.73, CI = -0.82 to -0.59, p < 0.001) (see Figure 3). For exploratory purposes,
there was a weak, positive association found between FACT-G and CANTAB Z-score (r
= 0.16, CI = -0.09 to 0.39, p = 0.21).
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Figure 3: Association Between PAIS-SR and FACT-G
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Chapter V
Discussion
This correlational design allowed an exploration into the impact that chemotherapyinduced cognitive impairment has upon the non-metastatic colorectal cancer patient's
psychosocial adjustment and quality of life. This design was useful in that it only looked
at colorectal cancer patients who had had surgery, the main difference being whether one
had chemotherapy treatment or not. Using such a design has an advantage over using a
healthy control group, since the characteristics affecting colorectal cancer patients'
psychosocial adjustment (Greer, 1994; Harrison & Maguire, 1994; Northouse et al., 2000)
and quality of life (Arndt et al., 2004; Cameron, 2005, Esnaola et al., 2002, Rauch et al.,
2004; Trentham-Dietz et al., 2003) are unique.
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In assessing cognitive function, this study was useful in that it looked at subsets of
patients assessed prior to and after chemotherapy administration. For the most part,
previous research into cognitive function has assessed cancer patients after commencing
chemotherapy and some has even begun assessing patients after chemotherapy
completion. These methods limit the study's findings to patient recall, and the level of
patient functioning prior to treatment administration is unknown. This current study is
useful in that colorectal cancer patients were assessed cross-sectionally at various time
points in the disease and treatment trajectories.
Research Questions
1. What impact does adjuvant chemotherapy-induced cognitive dysfunction have
upon the colorectal cancer patient's psychosocial adjustment?
The weak, negative correlation between cognitive function (CANTAB) and
psychosocial adjustment (PAIS-SR) is statistically non-significant. Additionally, the
differences in Total PAIS-SR T-scores of those who did and did not have a cognitive
deficit also indicate that cognitive impairment and psychosocial adjustment are not
related. Therefore, if a true association between these variables does exist, it is unlikely
to be sufficiently strong enough to be of much clinical significance.
It is interesting to note that no significant differences in cognitive function were
seen between the groups for either the CANTAB score or individual tests. This finding
corroborates with Bender et al. (2006) who found no differences between women with
breast cancer who recently completed chemotherapy and a breast cancer control group.
This study also concurs with Iconomou et al. (2004) who found that objective cognitive
performance was not affected by the type of chemotherapy, the type of cancer, or disease
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stage. Collectively, these findings suggest that neither treatment allocation or disease
stage affect the non-metastatic cancer patient's cognitive function.
Of Iconomou et al.'s (2004) mixed cancer sample, 15% demonstrated cognitive
impairment, which is slightly lower than the patients who were treated with
chemotherapy in this study. This difference may be due to their heterogeneous cancer
sample, which encompasses the issues of many cancer populations. This slight difference
may also illuminate the unique needs of the colorectal cancer patient.
The median PAIS-SR Total T-score found in this study was similar to that found by
Kelman (1997) in her study exploring psychosocial adjustment and colorectal cancer
patients with an ostomy (50 and 46.5 respectively). When looking at the Total PAIS-SR
scores among the groups, their differences approached statistical significance (p = 0.049).
However, it is important to note that none of the groups* median result indicated
psychosocial maladjustment as defined by the Total T-score >62. This could indicate
that as a group, stage of disease, treatment allocation, and time from diagnosis do not
affect the non-metastatic colorectal cancer patient's psychosocial adjustment.
2. Does psychosocial adjustment differ between people diagnosed with colorectal
cancer who do and do not receive adjuvant chemotherapy?
Psychosocial Adjustment, and specifically Sexual Relations and Social
Environment, differ between groups of colorectal cancer patients who do and do not
receive chemotherapy. These significant differences have been detailed previously.
When looking at the ranges of PAIS-SR Total T-scores for each group, it is clear
that participants in each of the groups had results indicating psychosocial maladjustment.
An exploration into the modes of each score found that 6 in Group A, 4 in Group B, 3 in
Group C, and 1 in Group D indicated maladjustment (n = 19, 18, 20, 17 and proportions
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are 31.5%, 22%, 15% and 5.8% respectively). These modes and proportions are also of
interest in that they may indicate that patients who receive chemotherapy have poorer
psychosocial adjustment than those who do not receive chemo, but that as time goes by,
both groups' psychosocial adjustment improve. This suggestion is strengthened by the
statistically significant difference found between the post-chemotherapy and 6-month
post-operative groups.
When attempting to compare the above results with the literature, it was difficult to
find longitudinal studies assessing psychosocial adjustment over time in colorectal cancer
patients receiving chemotherapy. However, the psychosocial adjustment of colorectal
cancer patients having had surgery has been assessed over time. Although they claim that
most (70%) of their sample did not receive chemotherapy, the study conducted by
Northouse et al. (2000) focused on the psychosocial adjustment of patients for 1-year
after colon surgery: no distinguishing analyses were made between the chemotherapy and
non-chemotherapy patients. They found the poorest scores of psychosocial adjustment
occurred within 2 months of diagnosis and then began to drop to near baseline levels at 1year. Similarly, Bekkers et al. (1997) found that the psychosocial problems that occurred
within the first four post-operative months were not demonstrated at 1-year after surgery.
Bekkers et al. also found that the surgery alone, apart from a cancer diagnosis, was the
largest contributor of psychosocial problems. Collectively, these studies show the
negative effect that chemotherapy and/or disease severity, as well as the positive effect
that duration since cancer treatment has upon the colorectal cancer patient's psychosocial
adjustment.
Derogatis and Derogatis (1990) claim that the domain scores of the PAIS-SR
provide an illustration relative to the benefits and burdens in the patient's adjustment and
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may identify areas where increased attention can be directed on the part of the health care
team. In reference to the Sexual Relations (SR) domain, the 6-months post-surgery group
significantly differed from both chemotherapy groups. This finding also suggests the
impact of cancer treatment upon the sexual relationships of colorectal cancer patients and
provides strength to the importance of disease stage. Simply put, it appears that more
advanced cancer requiring more aggressive treatments, more adversely affects the sexual
relationships of colorectal cancer patients. When considering the treatment side-effects of
these more aggressive treatments, it is easily plausible that the physiological
manifestations of treatment affect these people's sexual interests and performance.
Significant differences within the Social Environment (SE) domain were found
between the groups, with the post-chemotherapy group having highest scores for
impairment within their social and leisure activities. Again, these scores may be related
to the physiologic symptoms that occur with chemotherapy treatments, keeping patients
away from social settings that they previously enjoyed.
For all subscales and the Total T score, the median score among the 6-months postsurgical control patients was lowest, indicating highest psychosocial functioning. As
previously hypothesized, this may be related to the lower stage of disease and longer
duration post cancer treatment. Conversely, for all domains except the Vocational
Environment (VE) and Domestic Environment (DE), the median score amongst postchemotherapy patients was highest, indicating lowest functioning. This shows the broad
impact of chemotherapy upon a colorectal cancer patient's psychosocial adjustment, even
after completing treatment. It is only the VE and DE that is more severely affected when
beginning chemotherapy, which seems reasonable due to the uncertainty surrounding this
time in the disease trajectory.
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3. What is the relationship between psychosocial adjustment and quality of life
•within a sample of colorectal cancer patients?
The Pearson correlation coefficient for PAIS-SR Total T-score and FACT-G was
estimated to be - 0.73, which was statistically significant. Munro (2001) defines a
correlation of 0.70 - 0.89 as high. Since higher scores of the PAIS-SR indicate
maladjustment, and higher scores of the FACT-G indicate better quality of life, a negative
correlation indicates that the results of the tools are related. Therefore, from the results of
this study sample, it can be inferred that a relationship exists between psychosocial
adjustment and quality of life with a high degree of strength. Alternatively stated, those
with fewer psychosocial problems report higher quality of life.
When comparing study groups, quality of life (FACT-G) scores were shown to be
statistically significant (p-value = 0.028). Of particular interest, is the high median
FACT-G scores of those commencing chemotherapy as well as the 6-month post-surgery
control group although the range of scores in the 6-month post-operative control group
were higher. There is no clarity to these differences found in the literature. When
looking at the quality of life of patients with locally recurrent rectal cancer, Esnaola et al.
(2002) found that disease status, being disease free or having residual disease, had no
effect on quality of life (p = 0.2). This study could help explain this lack of difference
between disease stages in this study.
Esnaola et al. (2002) also suggested a decline in quality of life scores during the first
year after surgery. Although their analysis did not focus on the differences between those
receiving and not chemotherapy, it is easily seen that 34 of the 45, or 75%, of the patients
received chemotherapy. Their finding concurs with the median scores of the treatment
groups in this study showing a higher FACT-G score prior to chemotherapy as compared
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to after chemotherapy. An explanation of the rising median scores of the surgery only
groups could be that the duration after cancer treatment, or surgery in this case, results in
an increasing quality of life. It would have been interesting to note if this same finding
would have been seen in the chemotherapy groups if this study had of assessed patients 6months after their chemotherapy treatments.
Of the FACT-G subscales, the post chemotherapy group significantly differed from
the other groups in terms of the Physical Well-Being (p = 0.037) and Social Well-Being
(p = 0.042) subscales. These differences could possibly be explained by the physical
side-effects that accumulate during chemotherapy for colorectal cancer and thus remove
these patients from their previously enjoyed activities.
Implications for Nursing
Although no significant differences in cognitive function were seen between the
groups for either the CANTAB score or individual tests, it is important for nurses to
recognize that cognitive deficits were found in each of these treatment groups. Since
these findings further generalize those that are found within the oncology literature,
nurses need to know that cognitive disturbances can occur at any time in the disease or
treatment trajectory, and thus assess and arrange for appropriate interventions.. Due to
nurses' frequent proximity to cancer patients, they are in a unique position to provide
ongoing assessments of patients' cognitive performance while undergoing cancer
treatment and follow-up. Although detailed neurocognitive testing is conducted by those
with an extensive psychology background, nurses can be a patient's first step toward such
testing and treatment of these difficulties. Further research into the development or
institutional formatting of an existing assessment tool for chemotherapy induced
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cognitive impairment would be useful for front-line nurses caring for cancer patients.
This would be a useful multi-disciplinary research project.
In terms of psychosocial adjustment, the results from this sample further generalize
that found within the oncology literature. However, it is important to note that none of
the treatment groups' median score showed mal-adjustment, but that in exploring the
modes, those beginning chemotherapy had a higher proportion of maladjusted scores.
This is useful for nurses so that they can more closely assess psychosocial adjustment
when their patients begin chemotherapy. When looking at the median subscale scores for
this group of patients, nursing assessments should be targeted toward factors relating to
patients' sexual relationships and social environment. The items that Derogatis and
Derogatis' (1990) list as variables of interest for each domain can be easily assessed
during a patient assessment. An assessment into the cancer patient's sexual relationships
would assess the patient's perceived quality of the interpersonal relationship, moving
toward more specific issues about their interest, frequency, satisfaction and/or
dysfunction (Derogatis & Derogatis, 1990). Their social environment assessment
encompasses leisure interests and activities that they enjoy individually, with their family
and as part of a larger social network (Derogatis & Derogatis, 1990). These assessments
both open the door for patient expression of concerns that are infrequently assessed as
part of mainstream practice. This dialogue allows for intervention suggestions and
referral opportunities.
It is also useful to know that psychosocial adjustment and quality of life are related,
as evidenced by the correlation in PAIS-SR and FACT-G scores. This could be useful for
any future research projects, not only those related to nursing.

62
Implications for the Theory of Unpleasant Symptoms
The Theory of Unpleasant Symptoms is useful to guide the understanding of
chemotherapy-induced cognitive impairment upon the psychosocial adjustment and
quality of life in colorectal cancer patients. The association between performance, or
cognitive impairment as indicated by the CANTAB, and influencing factors, as indicated
by the PAIS-SR and FACT-G results, was shown to be minimally present and statistically
non-significant. The claim for interactions among the influencing factors is strengthened
by the statistically significant association between the PAIS-SR and FACT-G. Therefore,
this study shows mixed support for the concepts within the Theory of Unpleasant
Symptoms. It is important to note that this theory does have usefulness although this
study's findings were non-significant. Such findings warrant further usage of this theory
within oncology research projects.
Limitations of the Study
One seeming limitation of this study was to use a cross-sectional methodology. It is
well known that prospective studies provide more useful information when looking for
associations between variables. Therefore, assessing colorectal cancer patients for a
duration of time, using serial assessments would have been a more beneficial model to
answer the research questions of this study. Also related to the above limitation, a
longitudinal, prospective study would be been useful to assess the seeming importance of
duration after a colorectal cancer patient's cancer treatment.
Conclusion
In this subset of colorectal cancer patients, there appears to be a weak, negative
association between cognitive impairment and psychosocial adjustment, however the
level of association was not significant statistically. Thus, if there is a true association
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between these variables, the association is unlikely to be sufficiently strong to be of much
clinical significance.
In terms of psychosocial adjustment and treatment groups, the Total PAIS-SR Tscores reached statistical significance. Significant differences were found between the
groups for the Sexual Relations, and Social Environment domains.
Regarding the association between the psychosocial adjustment and quality of life,
there was an inversely strong relationship found between the measures indicating that
fewer psychosocial problems resulted in a higher quality of life.
Although the cited limitations of this study are acknowledged, this study is useful
for health care professionals working with cancer patients to understand chemotherapyinduced cognitive impairment, psychosocial adjustment and quality of life in colorectal
cancer patients.
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The Impact of Cognitive Dysfunction Upon the Non-Metastatic Colorectal Cancer
Patient's Psychosocial Adjustment and Quality of Life
(For patients who will receive and who completed chemotherapy)
You are asked to participate in a research study conducted by Jacqueline Galica, a
Graduate Student from the Faculty of Nursing at the University of Windsor, and her
Principal Advisor, Dr. Deborah Kane, Associate Professor at the University of Windsor.
The results of this study will be used to contribute to Jacqueline's thesis research within
the Master of Science degree requirements.
Before agreeing to participate in this study, it is important that you read and understand
the following explanation of the proposed study procedures. The following information
describes the purpose, procedures, benefits, discomforts, risks and precautions associated
with the study. It also describes your right to refuse to participate or withdraw from the
study at any time. In order to decide whether you wish to participate in this research
study, you should understand its risks and benefits to be able to make an informed
decision. This is known as the informed consent process. Please ask the study staff to
explain any words that you don't understand before signing this consent form. Make sure
all of your questions have been answered to your satisfaction before signing this
document.
PURPOSE OF THE STUDY
As a patient who will be receiving chemotherapy to try to prevent further problems from
your bowel cancer, you have received information from your doctors about several
possible side effects of treatment. You are participating in a study that will try to obtain
information about side effects that might also occur as a result of your treatment, but
which are often harder to measure. These possible side effects include tiredness, and
subtle changes in your ability to think, concentrate, remember and react to things. You
are now being asked to take part in another study that will try to determine how these side
effects impact your personal and professional roles and functioning.

PROCEDURES
The study will involve completing a questionnaire in a quiet environment at your leisure.
The approximate time that it takes to complete this questionnaire is 20-25 minutes. After
completion, you will be asked to mail the completed questionnaire in the postage paid
return address envelope. You will only be asked to complete this questionnaire one time.
By consenting to this study, you are agreeing to allow the researcher to access your
demographics and results of the cognitive assessment and questionnaires that you
completed within the larger study that you are participating in.
POTENTIAL RISKS AND BENEFITS TO SUBJECTS AND/OR TO SOCIETY
There are no known risks associated with the study. It will not change your medical
treatment in any way. There are also no direct benefits to you. The aim is to find out
more information about side effects of chemotherapy. This information will be used to
give better advice to patients like you who receive chemotherapy in the future.
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If you become ill or are physically injured as a result of participation in this study,
medical treatment .will be provided. The reasonable costs of such treatment will be
covered by your health insurance for any injury or illness that is directly a result of
participation in this study. In no way does signing this consent form waive your legal
rights nor does it relieve the investigators, sponsors or involved institutions from their
legal and professional responsibilities.
PAYMENT FOR PARTICIPATION
You will not receive payment for your participation in this study. It is not expected that
you should incur any expenses as a result of your participation.
CONFIDENTIALITY
All information obtained during this study will be held in strict confidence. You will be
identified with a study number only. No names or identifying information will be used in
any publication or presentations. No information identifying you will be transferred
outside the investigators in this study or this hospital. The individual questionnaires and
results will be destroyed after the study analysis has taken place.
PARTICIPATION AND WITHDRAWAL
Your participation in this study is voluntary. You can choose not to participate or you
may withdraw at any time without affecting your medical care.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS
Individual results will not be routinely given to participants. However, if participants
would like to know the results of their assessment, they may contact the research
investigator directly. Participants may also review the overall outcomes of the study in
the 'Study Results' section on the University of Windsor's REB website at
www.uwindsor.ca/reb.
RIGHTS OF RESEARCH SUBJECTS
If you suffer any side effects or other injuries during the study, or if you have any general
questions about the study, please call the person in charge of this study, Jacqueline Galica
at (416) 946-4501 extension 3176.
If you have questions about your rights as a research participant, please call Dr. R.
Heslegrave, Chair of the University Health Network Research Ethics Board at (416) 3404557. You may also contact the Research Ethics Coordinator at the University of
Windsor, (519) 253-3000 extension 3916. These people are not involved with the
research project in any way and calling them will not affect your participation in the
study.
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE
I have had the opportunity to discuss this study and my questions have been answered to
my satisfaction. I consent to take part in the study with the understanding that I may
withdraw at any time without affecting my medical care. I have received a signed copy
of this consent form. I voluntarily consent to participate in this study.
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Study Subject's Name (Please Print) Study Subject's Signature

Date

SIGNATURE OF INVESTIGATOR
I confirm that I have explained the nature and purpose of the study to the subject named
above. I have answered all questions.

Name of Person
Obtaining Consent

Signature

Date
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The Impact of Cognitive Dysfunction Upon the Non-Metastatic Colorectal Cancer
Patient's Psychosocial Adjustment and Quality of Life
(For patients who do not need chemotherapy)
You are asked to participate in a research study conducted by Jacqueline Galica, a
Graduate Student from the Faculty of Nursing at the University of Windsor, and her
Principal Advisor, Dr. Deborah Kane, Associate Professor. The results of this study will
be used to contribute to Jacqueline's thesis research within the Master of Science degree
requirements.
Before agreeing to participate in this study, it is important that you read and understand
the following explanation of the proposed study procedures. The following information
describes the purpose, procedures, benefits, discomforts, risks and precautions associated
with the study. It also describes your right to refuse to participate or withdraw from the
study at any time. In order to decide whether you wish to participate in this research
study, you should understand its risks and benefits to be able to make an informed
decision. This is known as the informed consent process. Please ask the study staff to
explain any words that you don't understand before signing this consent form. Make sure
all of your questions have been answered to your satisfaction before signing this
document.
PURPOSE OF THE STUDY
As a patient who has been diagnosed with bowel cancer and has had surgery for this, but
who either does not need to have chemotherapy or does not wish to have chemotherapy,
you have been asked to participate in a study that will try to obtain information about side
effects of chemotherapy. These include tiredness, and subtle changes in the ability to
think, concentrate, remember and react to things. You are now being asked to take part in
another study that will try to determine how these side effects impact patients' personal
and professional roles and functioning.

PROCEDURES
The study will involve completing a questionnaire in a quiet environment at your leisure.
The approximate time that it takes to complete this questionnaire is 20-25 minutes. After
completion, you will be asked to mail the completed questionnaire in the postage paid
return address envelope. You will only be asked to complete this questionnaire one time.
By consenting to this study, you are agreeing to allow the researcher to access your
demographics and results of the cognitive assessment and questionnaires that you
completed within the larger study that you are participating in.
POTENTIAL RISKS AND BENEFITS TO SUBJECTS AND/OR TO SOCIETY
There are no known risks associated with the study. It will not change your medical
treatment in any way. There are also no direct benefits to you. The aim is to find out
more information about side effects of chemotherapy. This information will be used to
give better advice to patients like you who receive chemotherapy in the future.
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If you become ill or are physically injured as a result of participation in this study,
medical treatment will be provided. The reasonable costs, of such treatment will be
covered by your health insurance for any injury or illness that is directly a result of
participation in this study. In no way does signing this consent form waive your legal
rights nor does it relieve the investigators, sponsors or involved institutions from their
legal and professional responsibilities.
PAYMENT FOR PARTICIPATION
You will not receive payment for your participation in this study. It is not expected that
you should incur any expenses as a result of your participation.
CONFIDENTIALITY
All information obtained during this study will be held in strict confidence. You will be
identified with a study number only. No names or identifying information will be used in
any publication or presentations. No information identifying you will be transferred
outside the investigators in this study or this hospital. The individual questionnaires and
results will be destroyed after the study analysis has taken place.
PARTICIPATION AND WITHDRAWAL
Your participation in this study is voluntary. You can choose not to participate or you
may withdraw at any time without affecting your medical care.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS
Individual results will not be routinely given to participants. However, if participants
would like to know the results of their assessment or study, they may contact the research
investigator directly. Participants may also review the overall outcomes of the study in
the 'Study Results' section on the University of Windsor's REB website at
www.uwindsor.ca/reb.
RIGHTS OF RESEARCH SUBJECTS
If you suffer any side effects or other injuries during the study, or if you have any general
questions about the study, please call the person in charge of this study, Jacqueline Galica
at (416) 946-4501 extension 3176.
If you have questions about your rights as a research participant, please call Dr. R.
Heslegrave, Chair of the University Health Network Research Ethics Board at (416) 3404557. You may also contact the Research Ethics Coordinator at the University of
Windsor, (519) 253-3000 extension 3916. These people are not involved with the
research project in any way and calling them will not affect your participation in the
study.
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE
I have had the opportunity to discuss this study and my questions have been answered to
my satisfaction. I consent to take part in the study with the understanding that I may
withdraw at any time without affecting my medical care. I have received a signed copy
of this consent form. I voluntarily consent to participate in this study.
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Study Subject's Signature
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Date

SIGNATURE OF INVESTIGATOR
I confirm that I have explained the nature and purpose of the study to the subject named
above. I have answered all questions.

Name of Person
Obtaining Consent

Signature

Date
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Motor Screening
(MOT)

3 minutes

Big/Little Circle
(BLC)
\ iMi.il Vlonion ICMN
Delayed Matching
to Sample (DMS)

3 minutes

Paired Associates
Learning (PAL)
Pattern Recognition
Memory (PRM)
Spatial Recognition
Memory (SRM)

10 minutes

10 minutes
5 minutes
5 minutes

Win kiiii' \U"inoi\ .mil I' aiinin«j 1 i>is
Stockings of
10 minutes
Cambridge (SOC)
Spatial Span (SSP)
5 minutes

Spatial Working
Memory (SWM)
Intra-Extra
Dimensional Set
Shifting (IED)
Match to Sample
Visual Search
(MTS)
Reaction Time
(RTI)
Rapid Visual
Information
Processing (RVP)

8 minutes
7 minutes
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Designed to relax the participant and introduce them to
the computer and touch screen. Screens for visual,
movement and comprehension difficulties.
A test of following a simple rule and then reversing it.
Assess comprehension learning and reversal.
Tests simultaneous and delayed matching to a sample.
Sensitive to damage in the medial temporal lobe, with
some input from the frontal lobes.
Assesses visual memory and new learning.
Assesses the ability to recognize a previously viewed
pattern.
A test of spatial recognition memory where the subject
tries to remember where which object is located in the
location where it was previously seen.
A test where the subject is to copy a given pattern.
Assesses spatial planning and motor control.
Assesses working memory capacity whereby the
subject touches a sequence of objects in the same order
that they were presented.
Tests ability to retain spatial information and
manipulate remembered items in working memory.
A test of rule acquisition and reversal. Assesses visual
discrimination and flexibility and shifting of attention.

9 minutes

Tests the ability of matching visual stimuli while
measuring reaction and movement time

5 minutes

Measures the speed of response to a visual target where
the stimulus is either predictable or unpredictable.
Tests visual sustained memory. Subjects are given 3
number sequences to remember and then press a touch
pad when a sequence appears.

7 minutes

\lllllll01Kil ICMS

Affective Go/No-go
(AGN)

10 minutes

Verbal Recognition
Memory (VRM)

20 minutes
(2 modes)

A series of words are flashed on the screen and
subjects touch pad when a word of an indicated
valence (positive, negative or neutral) is shown.
Assesses immediate and delayed memory of verbal
information by remembering as many presented words
as possible and then indicating previously presented
words in a subsequent presentation.
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Appendix D - Psychosocial Adjustment to Illness Scale - Self Report Version (PAIS-SR)
Sample Items
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Psychosocial Adjustment to Illness Scale - Self Report Version (PAIS-SR) Sample Items
Copyright 1978, 1983 by Leonard R. Deogatis, PhD
INSTRUCTIONS
The present form contains questions concerning the effects that your illness has
had on you. We are interested in knowing what effects it has had on your relationships
and your ability to perform at home and on your job. Also, we would like to know about
the effects on family and personal relationships. Other questions concern its effect on
your social and leisure time activities, and how you have felt emotionally.
In answering each question, please put a check mark (V) in the box alongside the
answer that best describes your experience. Please answer all the questions and try not to
skip any. If none of the answers to a question match your experience exactly, please
choose the answer that comes closest to the experience you have had.
The time we would like to refer to is the past 30 days, including today. Answer
each question in terms of what your experience has been like during this time frame. In
the event you are presently a patient in the hospital, please report your experiences for
the 30 days before entering the hospital.
Some questions on the form assume that you are married or have a steady partner
you are close to. Other questions ask about family relationships. If these questions do
not apply to you because you are unmarried, or you have no family or partner, please
leave them blank. Try to answer all the questions that do apply to you, however.
Section II asks questions about your job performance. If you have either full-time
or substantial part-time employment, please answer in terms of your job. If you are
primarily a student, answer in terms of your schoolwork. If you are a housewife, answer
as though housework, neighbours, etc. are your work environment.

We appreciate the time you have taken to do this form. Please check again to
make sure you have completed all the items. If you have any questions about this form,
please ask. If you are responding by mail, please write them in the space provided below.
Please return the form as soon as you've completed it.
Thank You.

(Copyright and trademark laws do not permit the reproduction of the complete
Psychosocial Adjustment to Illness Scale. The following sample items are provided.)
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SECTION I
(1) Which of the following statements best describes your usual attitude about
taking care of your health?
[
[
[

]
]
]

[

]

a) I am very concerned and pay close attention to my personal health.
b) Most of the time I pay attention to my health care needs.
c) Usually, I try to take care of health matters but sometimes I just don't
get around to it.
d) Health care is something that I just don't worry too much about.

(2) Your present illness probably requires some special attention and care on your
part. Would you please select the statement below that best describes your
reaction.
[

]

[

]

[
[

]
]

a) I do things pretty much the way I always have done them and I don't
worry or take any special considerations for my illness.
b) I try to do all the things I am supposed to do to take care of myself, but
lots of times I forget or I am too tired or busy.
c) I do a pretty good job taking care of my present illness.
d) I pay close attention to all the needs of my present illness and do
everything I can to take care of myself.
SECTION II

(1) Has your illness interfered with your ability to do your job (schoolwork)?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

No problems with my job
Some problems, but only minor ones
Some serious problems
Illness has totally prevented me from doing my job

(2) How well do you physically perform your job (studies) now?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Poorly
Not too well
Adequately
Very well
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SECTION III
(1) How would you describe your relationship with your husband or wife (partner,
if not married) since your illness?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Good
Fair
Poor
Very Poor

(2) How would you describe your general relationships with other people you live
with (e.g., children, parents, aunts, etc.)?
[
[
[
[

]
]
]
]

a) Very Poor
b) Poor
c) Fair
d) Good
SECTION IV

(1) Sometimes having an illness can cause problems in a relationships. Has your
illness led to any problems with your husband or wife (partner, if not married)?
[
[
[
[

]
]
]
]

a) There has been no change in our relationship
b) We are a little less close since my illness
c) We are definitely less close since my illness
d) We have had serious problems or a break in our relationship since my
illness

(2) Sometimes when people are ill they report a loss of interest in sexual activities.
Have you experienced less sexual interest since your illness?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Absolutely no sexual interest since illness
A marked loss of sexual interest
A slight loss of sexual interest
No loss of sexual interest
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SECTION V

(1) Have you had as much contact as usual (either personally or by telephone) with
members of your family outside your household since your illness?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Contact is the same or greater since illness
Contact is slightly less
Contact is markedly less
No contact since illness

(2) Have you remained as interested in getting together with these numbers of your
family since your illness?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Little or no interest in getting together with them
Interest is a lot less than before
Interest is slightly less
Interest is the same or greater since illness
SECTION VI

(1) Are you still as interested in your leisure time activities and hobbies as you were
prior to your illness?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Same level of interest as previously
Slightly less interest than before
Significantly less interest than before
Little or no interest remaining

(2) How about actual participation? Are you still actively involved in doing those
activities?
[
[
[
[

]
]
]
]

a)
b)
c)
d)

Little or no participation at present
Participation reduced significantly
Participation reduced slightly
Participation remains unchanged
SECTION VII

(1) Recently, have you felt afraid, tense, nervous, or anxious?
[

] a) Not at all [

] b) A little bit

[

] c) Quite a bit [ ] d) Extremely

(2) Recently, have you felt sad, depressed, lost interest in things, or felt hopeless?
[ ] a) Extremely [ ] b) Quite a bit [ ] c) A little bit [ ] d) Not at all
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FACT-G (Version 4)
Below is a list of statements that other people with your illness have said are important. By
circling one (1) number per line, please indicate how true each statement has been for
you during the past 7 days.
PHYSICAL WELL-BEING
I have a lack of energy

Not
at all
0

A little Somebit
what
1 2

Quite
a bit
3

Very
much
4

I have nausea

0

Because of my physical condition, I have
trouble meeting the needs of my family...

0

1

2

3

4

GP4

I have pain

0

1

2

3

4

GP5

I am bothered by side effects of

0

1

2

3

4

I feel ill

0

1

3

4

I am forced to spend time in bed

0

1

2

3

4

Not
at all

A little
bit

Somewhat

Quite
a bit

Very
much

I feel close to my friends

0

1

2

3

4

I get emotional support from my family ....

0

1

2

3

4

I get support from my friends

0

1

2

3

4

My family has accepted my illness

0

1

3

4

0

1

2

3

4

0

1

2

3

4

1

2

3

4

GP2

.

treatment

SOCIAL/FAMILY WELL-BEING

I am satisfied with family
communication about my illness
I feel close to my partner (or the person
who is my main support)
Ql

2

2

Regardless of your current level of sexual activity,
please answer the following question. If you
prefer not to answer it, please check this box
and go to the next section.
I am satisfied with my sex life

US English
Copyright 1987, 1997

0
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By circling one (1) number per line, please indicate how true each statement has
been for you during the past 7 days.
Not
at all

A little
bit

I feel sad.

0

1

I am satisfied with how I am coping
with my illness

0

I am losing hope in the fight against my
illness

0

I feel nervous

0

I worry about dying
I worry that my condition will get worse...

EMOTIONAL WELL-BEING

GE2

GE6

FUNCTIONAL WELL-BEING

Somewhat

Quite
a bit

Very
much

0

2

3

4

0

2

3

4

A little
bit

Somewhat

Quite
a bit

Very
much

Not
at all

I am able to work (include work at
home)
GF2

GF3

GF5

GF6

GF7

My work (include work at home) is
fulfilling

0

I am able to enjoy life

0

1

2

3

4

I have accepted my illness

0

1

2

3

4

I am sleeping well

0

1

2

3

4

I am enjoying the things I usually
do for fun

0

1

2

3

4

I am content with the quality of my
life right now

0

US English
Copyright 1987. 1997

3/10/03
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3 - Wolters Kluwer
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Health
DATE: Wt22m
Jacqueline Galka, RM. BScK, MSc(c)

Fee: $0.00
Re: 4rfw»<:<« /* tuning Science
Spec Mist: AN$, 15>97, \<*;3\ J4-27. Fig. 2,
Thesis use- non-coinmsrcial
CONDITIONS
Permission is granted for your requested USB. Retain this copy for your records. This permission
is subject to tic following conditions:
1) A citdii Hue will x pr jinijfeiiily placed and included: for books - the iiulhunfs), title oJ'
book, editor, copyright holder, year of publication: for journals - the authors), title o f
article, litis t i f journal, volinic mm: her, issue number a i d inclusive poses.
2)

The requestor warrants It uL llie material sdiall not be used in anv immixjr w i t c h may be

considered deic-ggtory ID die titl*, content, or author(s) of the material or to Wolwre
Khmer Health.
. .V) Permission i* granluJ lor one time use only as specified in your cotrespciKlefKe, Rights
litrisiii do not apply to :\miit reproductions, editions, revisions, or oilier derivative works.
4) Permission granted is non-exclusive, and is vitid throughout the wcrfd in the English
language only.
5) Wolteis Kluwer Health CMtnrt supply the requestor with thenriginEl artwork or a "clean
copy."
6)

i herequestoragrees to secure wilier, permiisioik from die author (fot boot material
only).

7) ftrrniss.ii.iii !* valid if the bnnowed materiel is eriginui lu it Vull«n> K lnwei 1 "ealth
ii«r>iinr(l ippincotr, Williams & Wiikiiis. LtppinCOtt'Raven Publisher'.. Williams &
Wilkins, i-ea & Febifier, llarwal, Igatal-Shoht, R»pic fcience, Litile Brown and
Company, Umyet & Row Medical American Journal of Ximiftg Co. and Urban &
Schwarzcnbcrg- Rnglisfi Language).
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From: David Hart [David.Hart@camcog.com]
Sent: Wednesday, August 13, 2008 5:25 AM
To: Galica, Jacqueline
Subject: re: CANTAB information
Dear Jacqueline,
Thank you for the email. With regard to using CANTAB, the gold standard CANTABeclipse (see
datasheet above for details) package for academic research is currently the complete portable
CANTABeclipse 10-year system which is available as standard at a total (ex-works) cost of
£10,200. This provides unlimited use over a 10-year period of the full suite of twenty-two
CANTAB tests running on the standardised lightweight portable SlimBook panel touchscreen PC.
The software includes the child and adult test versions, parallel forms, child and adult normative
databases, software user and test administration manuals, software key, 3 months technical
support and a free training placement on one of the CANTABeclipse administrator training days in
Cambridge. These systems are dispatched fully commissioned with all of the CANTABeclipse
and platform software so that following delivery testing can begin immediately on power-up.
The 10-year CANTABeclipse software can be purchased without any hardware at £7,700 per site
(a 'site' is a single PC running the software for testing subjects). Clip-on touchscreens for desktop monitors and laptop screens can be provided by CCL from £275 if necessary.
If the 10-year software is too expensive for the budget or simply provides more than your study
protocol requires, then either the CANTABeclipse 1-year custom software, the CANTABeclipse 1year modular software or the CANTABeclipse 4-year modular software may be more attractive
options. These provide the same features and benefits as the 10-year software but at a lower
cost based on a shorter licence period and access to fewer tests - either individual tests (with the
custom licence) or seven tests (with the modular licence) cherry-picked from the full battery of
twenty-two.
With the SlimBook touchscreen PC included, the standard full system cost is currently £3,250
(one test) to £4,000 (four tests) for the 1-year custom option, and £4,100 (1-year) to 7,200 (4year) for the seven test modular option. Without the hardware, the cost is £750 to £1,500 for the
1-year custom software, and £1,600 to £4,700 for the modular versions. The custom and modular
software licences include the associated child and adult test versions as well as parallel forms
depending on which tests are selected, child and adult normative databases, software user and
test administration manuals, software key and 3 months technical support.
I hope this information helps with regard to using CANTAB with your masters thesis. Please do
not heistate to contact us if we are able to provide additional detilas or you have any queries.
With very best wishes
David
David T Hart
Business Development Manager
Academic Research (UK and ROW)
Cambridge Cognition Ltd
tel:+44 (0)1223 810700
fax: +44 (0) 1223 810701
mobile: +44 (0) 7899 790762
email: david.hart@camcog.com
web: www.cantab.com
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From: MDero@aol.com
Sent: Monday, September 19, 2005 3:59 PM
To: Galica, Jacqueline
Subject: PAIS-SR Instrument
Dear Ms. Galica,
We recently received an e-mail from you concerning credentials necessary for using the PAISSR. Because you are doing you thesis and will have an advisor/supervisor working with you, you
definitely will qualify to use the PAIS-SR.
Once you have completed and submitted a Qualification form from our Log In button on our
website, www.deroqatis-tests.com , we will provide you with a User ID and password and you
can order directly from our website.
If you have any questions concerning this process, please do not hesitate to contact me.
Sincerely,
MDero@aol.com

From: MDero@aol.com
Sent: Wednesday, December 14, 2005 9:54 AM
To: Galica, Jacqueline
Subject: Re: PAIS-SR Instrument Publication Guidelines
December 14, 2005
Dear Ms. Galica,
Our guidelines are, - you can include up to 2 sample items from each of the PAIS-SR domaines.
We do not allow reproductions of the entire scale in any publications. Thank you for checking
with us concerning this matter.
If you have any further questions, please do not hesitate to contact us.
Sincerely,
MDerogatis
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Functional Assessment of Chronic nines® Therapy
• USER'S AGREEMENT

License for use of any English version of a FACIT measure is granted free of charge. Investigators are
required to complete one (1) collaborator's project information form for every project or study in which they
plan on using one or more of the FACIT measures, and to notify us of any related reports or publications as
they become available. Since scale construction and validation are developmental processes, we also
appreciate a willingness on the part of the investigators) to share relevant components of their results to
further reliability and validity testing (where applicable and appropriate).
License for use of a translated questionnaire may also require a fee. This decision is made on an individual
project basis according to the nature of the trial, the questionnaires and translations to be used, the sponsor,
and standing contractual arrangements. In general, there is a licensing fee for pharmaceutical and biotech
companies to use the translated questionnaires in clinical trials of a commercial nature. For more
information, please refer to the translation methods and services licensure link.
All translations, adaptations, symptom indices, computer programs, and scoring algorithms, and any other
related documents of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System,
including the Functional Assessment of Cancer Therapy (FACT), are owned and copyrighted by, and the
intellectual property of, David Cella, Ph.D. Copyright protection is also extended to electronic versions of all
FACIT documents and products. For more information on the copyright please refer to the copyright link.
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